SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'P16'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_A_STIA201_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 TYR A 272 VAL A 275 ALA A 288 GLU A 305 MET A 309 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.83A	1iepA-1opkA: 34.6	1iepA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_A_STIA201_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 THR A 334 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.70A	1iepA-1opkA: 34.6	1iepA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_A_STIA201_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 6	LYS A 290 VAL A 308 VAL A 318 ILE A 332	P16 A 2 (-4.5A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A)	0.60A	1iepA-1opkA: 34.6	1iepA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_A_STIA201_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 6	VAL A 308 VAL A 318 ILE A 332 MET A 337	None P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None	0.50A	1iepA-1opkA: 34.6	1iepA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_B_STIB202_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 TYR A 272 VAL A 275 ALA A 288 GLU A 305 MET A 309 THR A 334 GLY A 340	P16 A 2 ( 4.2A) P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-3.4A)	0.77A	1iepB-1opkA: 34.7	1iepB-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_B_STIB202_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 THR A 334 PHE A 336 GLY A 340 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-3.5A)	0.78A	1iepB-1opkA: 34.7	1iepB-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_B_STIB202_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 7	LYS A 290 VAL A 308 VAL A 318 ILE A 332 MET A 337 LEU A 389	P16 A 2 (-4.5A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None P16 A 2 (-4.4A)	0.65A	1iepB-1opkA: 34.7	1iepB-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_B_STIB202_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 7	VAL A 318 ILE A 332 MET A 337 ARG A 381	P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None None	0.94A	1iepB-1opkA: 34.7	1iepB-1opkA: 58.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1JLF_A_NVPA999_1 (HIV-1 RT A-CHAIN HIV-1 RT B-CHAIN)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 8	LEU A 346 VAL A 390 CYH A 388 GLY A 340	None None None P16 A 2 (-3.4A)	1.05A	1jlfA-1opkA: 2.2 1jlfB-1opkA: 1.9	1jlfA-1opkA: 21.60 1jlfB-1opkA: 21.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1M17_A_AQ4A999_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 ALA A 288 LYS A 290 GLU A 305 THR A 334 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.70A	1m17A-1opkA: 31.9	1m17A-1opkA: 25.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1ONI_A_BEZA502_0 (14.5 KDA TRANSLATIONAL INHIBITOR PROTEIN)	4crm	TRANSLATION INITIATION FACTOR RLI1 (Saccharomyces cerevisiae)	4 / 6	ASN P 5 ASN P 74 ILE P 56 GLY P 57	None None None SF4 P1610 ( 4.9A)	0.95A	1oniA-4crmP: undetectable 1oniB-4crmP: undetectable	1oniA-4crmP: 14.11 1oniB-4crmP: 14.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1ONI_D_BEZD508_0 (14.5 KDA TRANSLATIONAL INHIBITOR PROTEIN)	4crm	TRANSLATION INITIATION FACTOR RLI1 (Saccharomyces cerevisiae)	4 / 6	ASN P 5 ASN P 74 ILE P 56 GLY P 57	None None None SF4 P1610 ( 4.9A)	0.95A	1oniD-4crmP: undetectable 1oniF-4crmP: undetectable	1oniD-4crmP: 14.11 1oniF-4crmP: 14.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_A_STIA3_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	GLU A 305 MET A 309 ILE A 312 VAL A 318 THR A 334 LEU A 389 ALA A 399	P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.67A	1opjA-1opkA: 37.3	1opjA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_A_STIA3_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 VAL A 318 THR A 334 PHE A 336 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.60A	1opjA-1opkA: 37.3	1opjA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_A_STIA3_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 5	LYS A 290 VAL A 308 ILE A 332 MET A 337	P16 A 2 (-4.5A) None P16 A 2 (-4.1A) None	0.55A	1opjA-1opkA: 37.3	1opjA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_A_STIA3_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 5	TYR A 272 VAL A 308 ILE A 332 MET A 337	P16 A 2 (-3.6A) None P16 A 2 (-4.1A) None	0.75A	1opjA-1opkA: 37.3	1opjA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_B_STIB4_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	TYR A 272 VAL A 275 ALA A 288 GLU A 305 MET A 309 VAL A 318 THR A 334 GLY A 340	P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-3.4A)	0.77A	1opjB-1opkA: 37.1	1opjB-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_B_STIB4_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 VAL A 318 THR A 334 PHE A 336 GLY A 340 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-3.5A)	0.70A	1opjB-1opkA: 37.1	1opjB-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_B_STIB4_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	LEU A 267 LYS A 290 VAL A 308 ILE A 332 MET A 337	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) None P16 A 2 (-4.1A) None	0.53A	1opjB-1opkA: 37.1	1opjB-1opkA: 58.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1T46_A_STIA3_1 (HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 VAL A 318 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.42A	1t46A-1opkA: 30.7	1t46A-1opkA: 24.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 12	ALA A 288 GLU A 305 THR A 334 LEU A 373 HIS A 380	P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) None None	0.54A	1uwhA-1opkA: 26.6	1uwhA-1opkA: 21.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	ALA A 288 LYS A 290 GLU A 305 THR A 334 LEU A 373 HIS A 380	P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) None None	0.53A	1uwhB-1opkA: 26.5	1uwhB-1opkA: 21.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	VAL A 275 ALA A 288 GLU A 305 THR A 334 LEU A 373 HIS A 380	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) None None	0.66A	1uwjA-1opkA: 7.1	1uwjA-1opkA: 21.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	VAL A 275 ALA A 288 GLU A 305 THR A 334 LEU A 373 HIS A 380	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) None None	0.66A	1uwjB-1opkA: 7.1	1uwjB-1opkA: 21.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XKK_A_FMMA91_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	THR A 334 GLY A 340 LEU A 343 ASP A 344 ARG A 347 LEU A 389	P16 A 2 (-3.7A) P16 A 2 (-3.4A) None None None P16 A 2 (-4.4A)	0.75A	1xkkA-1opkA: 29.2	1xkkA-1opkA: 24.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XKK_A_FMMA91_2 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 9	LEU A 267 VAL A 275 LYS A 290 LEU A 320 MET A 337	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-4.5A) None None	0.64A	1xkkA-1opkA: 29.2	1xkkA-1opkA: 24.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_A_1N1A501_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	11 / 12	LEU A 267 ALA A 288 LYS A 290 GLU A 305 MET A 309 VAL A 318 ILE A 332 THR A 334 PHE A 336 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.82A	2gqgA-1opkA: 37.1	2gqgA-1opkA: 57.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_A_1N1A501_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	11 / 12	LEU A 267 ALA A 288 LYS A 290 MET A 309 VAL A 318 ILE A 332 THR A 334 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.80A	2gqgA-1opkA: 37.1	2gqgA-1opkA: 57.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_B_1N1B502_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 VAL A 318 ILE A 332 THR A 334 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.57A	2gqgB-1opkA: 37.9	2gqgB-1opkA: 57.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_B_1N1B502_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 MET A 309 VAL A 318 ILE A 332 THR A 334 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.62A	2gqgB-1opkA: 37.9	2gqgB-1opkA: 57.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_B_1N1B502_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 VAL A 318 ILE A 332 THR A 334 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.59A	2gqgB-1opkA: 37.9	2gqgB-1opkA: 57.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_B_1N1B502_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	VAL A 275 ALA A 288 LYS A 290 MET A 309 VAL A 318 ILE A 332 THR A 334 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.59A	2gqgB-1opkA: 37.9	2gqgB-1opkA: 57.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_A_STIA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	TYR A 272 VAL A 275 ALA A 288 GLU A 305 MET A 309 THR A 334 PHE A 336 GLY A 340 LEU A 389	P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.87A	2hyyA-1opkA: 34.9	2hyyA-1opkA: 99.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_A_STIA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 THR A 334 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.78A	2hyyA-1opkA: 34.9	2hyyA-1opkA: 99.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_A_STIA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	LEU A 267 LYS A 290 VAL A 308 VAL A 318 ILE A 332	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A)	0.59A	2hyyA-1opkA: 34.9	2hyyA-1opkA: 99.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_A_STIA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	LYS A 290 VAL A 308 VAL A 318 ILE A 332 ARG A 381	P16 A 2 (-4.5A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None	1.01A	2hyyA-1opkA: 34.9	2hyyA-1opkA: 99.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_B_STIB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	TYR A 272 VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 THR A 334 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.88A	2hyyB-1opkA: 34.7	2hyyB-1opkA: 99.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_B_STIB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 THR A 334 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.69A	2hyyB-1opkA: 34.7	2hyyB-1opkA: 99.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_B_STIB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	LEU A 267 LYS A 290 VAL A 308 VAL A 318 ILE A 332	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A)	0.54A	2hyyB-1opkA: 34.7	2hyyB-1opkA: 99.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_B_STIB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 6	LEU A 267 VAL A 308 ILE A 332 MET A 337	P16 A 2 ( 4.2A) None P16 A 2 (-4.1A) None	0.44A	2hyyB-1opkA: 34.7	2hyyB-1opkA: 99.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_C_STIC600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	11 / 12	TYR A 272 VAL A 275 ALA A 288 GLU A 305 ILE A 312 VAL A 318 THR A 334 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) None P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.84A	2hyyC-1opkA: 35.2	2hyyC-1opkA: 99.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_C_STIC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	LEU A 267 LYS A 290 VAL A 308 MET A 309 ILE A 332	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) None P16 A 2 (-3.3A) P16 A 2 (-4.1A)	0.53A	2hyyC-1opkA: 35.2	2hyyC-1opkA: 99.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_C_STIC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	LEU A 267 VAL A 308 MET A 309 ILE A 332 MET A 337	P16 A 2 ( 4.2A) None P16 A 2 (-3.3A) P16 A 2 (-4.1A) None	0.44A	2hyyC-1opkA: 35.2	2hyyC-1opkA: 99.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_D_STID600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	TYR A 272 VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 332 THR A 334 PHE A 336 LEU A 389 ALA A 399	P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.87A	2hyyD-1opkA: 34.8	2hyyD-1opkA: 99.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_D_STID600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 ILE A 332 THR A 334 PHE A 336 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.74A	2hyyD-1opkA: 34.8	2hyyD-1opkA: 99.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_D_STID600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 4	LEU A 267 LYS A 290 VAL A 318 MET A 337	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) None	0.58A	2hyyD-1opkA: 34.8	2hyyD-1opkA: 99.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ITO_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	LEU A 267 ALA A 288 LYS A 290 GLU A 305 MET A 309 THR A 334 GLY A 340	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-3.4A)	0.81A	2itoA-1opkA: 30.3	2itoA-1opkA: 25.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ITO_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	LEU A 267 ALA A 288 LYS A 290 GLU A 305 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.83A	2itoA-1opkA: 30.3	2itoA-1opkA: 25.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ITY_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.94A	2ityA-1opkA: 30.3	2ityA-1opkA: 24.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ITZ_A_IREA2021_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 THR A 334 GLY A 340	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-3.4A)	0.82A	2itzA-1opkA: 30.1	2itzA-1opkA: 24.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ITZ_A_IREA2021_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.89A	2itzA-1opkA: 30.1	2itzA-1opkA: 24.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2OIQ_A_STIA1001_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 ILE A 332 THR A 334 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.69A	2oiqA-1opkA: 31.7	2oiqA-1opkA: 30.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2PL0_A_STIA200_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	ALA A 288 GLU A 305 MET A 309 VAL A 318 ILE A 332 THR A 334 LEU A 389 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.74A	2pl0A-1opkA: 30.2	2pl0A-1opkA: 28.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2PL0_A_STIA200_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	ALA A 288 LYS A 290 GLU A 305 MET A 309 VAL A 318 ILE A 332 THR A 334 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.5A)	0.72A	2pl0A-1opkA: 30.2	2pl0A-1opkA: 28.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2PL0_A_STIA200_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 332 THR A 334 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.87A	2pl0A-1opkA: 30.2	2pl0A-1opkA: 28.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2PL0_A_STIA200_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 ILE A 332 THR A 334 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.5A)	0.78A	2pl0A-1opkA: 30.2	2pl0A-1opkA: 28.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2XP2_A_VGHA9000_1 (TYROSINE-PROTEIN KINASE RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 9	LEU A 267 VAL A 275 ALA A 288 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.58A	2xp2A-1opkA: 30.8	2xp2A-1opkA: 25.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y6O_A_1N1A1892_1 (EPHRIN TYPE-A RECEPTOR 4)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	ALA A 288 LYS A 290 GLU A 305 MET A 309 ILE A 332 THR A 334 GLY A 340 LEU A 389	P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.61A	2y6oA-1opkA: 31.7	2y6oA-1opkA: 26.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2YFX_A_VGHA9000_1 (TYROSINE-PROTEIN KINASE RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 8	LEU A 267 ALA A 288 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.50A	2yfxA-1opkA: 30.6	2yfxA-1opkA: 25.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ZJ0_A_2FAA500_2 (ADENOSYLHOMOCYSTEINA SE)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 5	GLN A 319 THR A 334 HIS A 380 LEU A 403	None P16 A 2 (-3.7A) None None	1.39A	2zj0A-1opkA: undetectable	2zj0A-1opkA: 21.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ZVA_A_1N1A513_1 (TYROSINE-PROTEIN KINASE LYN)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	11 / 12	LEU A 267 ALA A 288 LYS A 290 GLU A 305 MET A 309 VAL A 318 ILE A 332 THR A 334 MET A 337 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.76A	2zvaA-1opkA: 32.2	2zvaA-1opkA: 28.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ZVA_A_1N1A513_1 (TYROSINE-PROTEIN KINASE LYN)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	11 / 12	LEU A 267 ALA A 288 LYS A 290 MET A 309 VAL A 318 ILE A 332 THR A 334 MET A 337 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.77A	2zvaA-1opkA: 32.2	2zvaA-1opkA: 28.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3AOX_A_EMHA901_1 (ALK TYROSINE KINASE RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 10	LEU A 267 ALA A 288 VAL A 318 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 ( 4.7A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.74A	3aoxA-1opkA: 30.4	3aoxA-1opkA: 27.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3C7Q_A_XINA1172_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 GLU A 277 ALA A 288 LYS A 290 VAL A 318 PHE A 336 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) None P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.60A	3c7qA-1opkA: 29.6	3c7qA-1opkA: 26.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 10	LEU A 267 TYR A 272 VAL A 275 LYS A 290 LYS A 304 ILE A 332 PHE A 336	P16 A 2 ( 4.2A) P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-4.5A) None P16 A 2 (-4.1A) P16 A 2 ( 4.4A)	0.98A	3cs9A-1opkA: 34.8	3cs9A-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 10	LEU A 267 TYR A 272 VAL A 275 LYS A 290 VAL A 318 ILE A 332 PHE A 336	P16 A 2 ( 4.2A) P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 ( 4.4A)	0.82A	3cs9A-1opkA: 34.8	3cs9A-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 10	LEU A 267 VAL A 275 LYS A 290 VAL A 318 ILE A 332 PHE A 336 VAL A 398	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 ( 4.4A) None	0.64A	3cs9A-1opkA: 34.8	3cs9A-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	ALA A 288 GLU A 305 VAL A 308 MET A 309 LEU A 317 THR A 334 GLY A 340 HIS A 380 LEU A 389 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) None P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 (-3.4A) None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.59A	3cs9A-1opkA: 34.8	3cs9A-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	GLU A 305 VAL A 308 MET A 309 ILE A 312 LEU A 317 THR A 334 GLY A 340 HIS A 380 LEU A 389 ALA A 399	P16 A 2 (-4.2A) None P16 A 2 (-3.3A) None None P16 A 2 (-3.7A) P16 A 2 (-3.4A) None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.70A	3cs9A-1opkA: 34.8	3cs9A-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_B_NILB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	ALA A 288 GLU A 305 VAL A 308 MET A 309 ILE A 312 LEU A 317 THR A 334 GLY A 340 HIS A 380 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) None P16 A 2 (-3.3A) None None P16 A 2 (-3.7A) P16 A 2 (-3.4A) None P16 A 2 (-3.5A)	0.66A	3cs9B-1opkA: 34.3	3cs9B-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_B_NILB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 9	LEU A 267 TYR A 272 VAL A 275 LYS A 290 VAL A 318 ILE A 332 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-4.4A)	0.73A	3cs9B-1opkA: 34.3	3cs9B-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_B_NILB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 9	LEU A 267 VAL A 275 LYS A 290 VAL A 318 ILE A 332 LEU A 389 VAL A 398	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-4.4A) None	0.53A	3cs9B-1opkA: 34.3	3cs9B-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_B_NILB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 9	LEU A 267 VAL A 275 VAL A 318 ILE A 332 PHE A 378 LEU A 389 VAL A 398	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None P16 A 2 (-4.4A) None	0.68A	3cs9B-1opkA: 34.3	3cs9B-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	ALA A 288 GLU A 305 VAL A 308 MET A 309 ILE A 312 LEU A 317 THR A 334 PHE A 336 HIS A 380 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) None P16 A 2 (-3.3A) None None P16 A 2 (-3.7A) P16 A 2 ( 4.4A) None P16 A 2 (-3.5A)	0.68A	3cs9C-1opkA: 34.2	3cs9C-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	VAL A 308 MET A 309 ILE A 312 LEU A 317 THR A 334 PHE A 378	None P16 A 2 (-3.3A) None None P16 A 2 (-3.7A) None	1.37A	3cs9C-1opkA: 34.2	3cs9C-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 9	LEU A 267 VAL A 275 LYS A 290 VAL A 318 ILE A 332 MET A 337 VAL A 398	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None None	0.64A	3cs9C-1opkA: 34.2	3cs9C-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 9	TYR A 272 VAL A 275 VAL A 318 ILE A 332 MET A 337	P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None	1.00A	3cs9C-1opkA: 34.2	3cs9C-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_D_NILD600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	ALA A 288 GLU A 305 VAL A 308 MET A 309 LEU A 317 THR A 334 PHE A 336 GLY A 340 HIS A 380 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) None P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) None P16 A 2 (-3.5A)	0.59A	3cs9D-1opkA: 33.0	3cs9D-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_D_NILD600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	GLU A 305 VAL A 308 MET A 309 ILE A 312 LEU A 317 THR A 334 GLY A 340 HIS A 380 ALA A 399	P16 A 2 (-4.2A) None P16 A 2 (-3.3A) None None P16 A 2 (-3.7A) P16 A 2 (-3.4A) None P16 A 2 (-3.5A)	0.72A	3cs9D-1opkA: 33.0	3cs9D-1opkA: 57.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_D_NILD600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	LEU A 267 TYR A 272 VAL A 275 LYS A 290 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-4.5A) P16 A 2 (-4.4A)	0.72A	3cs9D-1opkA: 33.0	3cs9D-1opkA: 57.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G0E_A_B49A9000_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 11	LEU A 267 VAL A 275 ALA A 288 VAL A 318 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.39A	3g0eA-1opkA: 29.3	3g0eA-1opkA: 26.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G0F_A_B49A9001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 11	LEU A 267 VAL A 275 ALA A 288 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.38A	3g0fA-1opkA: 30.2	3g0fA-1opkA: 26.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3G0F_B_B49B9001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 10	LEU A 267 VAL A 275 ALA A 288 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.33A	3g0fB-1opkA: 30.5	3g0fB-1opkA: 26.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G5D_A_1N1A1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 VAL A 318 ILE A 332 THR A 334 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.58A	3g5dA-1opkA: 32.4	3g5dA-1opkA: 30.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G5D_A_1N1A1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 MET A 309 VAL A 318 ILE A 332 THR A 334 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.64A	3g5dA-1opkA: 32.4	3g5dA-1opkA: 30.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G5D_B_1N1B1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	11 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 VAL A 318 THR A 334 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.78A	3g5dB-1opkA: 32.5	3g5dB-1opkA: 30.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GVU_A_STIA1001_1 (TYROSINE-PROTEIN KINASE ABL2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 VAL A 318 THR A 334 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.61A	3gvuA-1opkA: 35.4	3gvuA-1opkA: 54.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GVU_A_STIA1001_1 (TYROSINE-PROTEIN KINASE ABL2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	TYR A 272 VAL A 275 ALA A 288 GLU A 305 MET A 309 VAL A 318 THR A 334 LEU A 389	P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-4.4A)	0.85A	3gvuA-1opkA: 35.4	3gvuA-1opkA: 54.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GVU_A_STIA1001_1 (TYROSINE-PROTEIN KINASE ABL2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 VAL A 318 THR A 334 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.72A	3gvuA-1opkA: 35.4	3gvuA-1opkA: 54.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GVU_A_STIA1001_2 (TYROSINE-PROTEIN KINASE ABL2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 5	LYS A 290 VAL A 308 ILE A 332 MET A 337	P16 A 2 (-4.5A) None P16 A 2 (-4.1A) None	0.60A	3gvuA-1opkA: 35.4	3gvuA-1opkA: 54.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IK3_A_0LIA1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	ALA A 288 GLU A 305 MET A 309 ILE A 312 LEU A 317 HIS A 380 LEU A 389 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None None None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.59A	3ik3A-1opkA: 34.8	3ik3A-1opkA: 57.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IK3_A_0LIA1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	GLU A 305 MET A 309 LEU A 317 VAL A 318 HIS A 380 LEU A 389	P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) None P16 A 2 (-4.4A)	0.63A	3ik3A-1opkA: 34.8	3ik3A-1opkA: 57.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IK3_A_0LIA1_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 7	LEU A 267 LYS A 290 VAL A 308 ILE A 332	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) None P16 A 2 (-4.1A)	0.53A	3ik3A-1opkA: 34.8	3ik3A-1opkA: 57.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IK3_A_0LIA1_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 7	LEU A 267 VAL A 308 ILE A 332 MET A 337	P16 A 2 ( 4.2A) None P16 A 2 (-4.1A) None	0.34A	3ik3A-1opkA: 34.8	3ik3A-1opkA: 57.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IK3_B_0LIB2_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	ALA A 288 GLU A 305 MET A 309 ILE A 312 LEU A 317 HIS A 380 LEU A 389 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None None None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.57A	3ik3B-1opkA: 34.6	3ik3B-1opkA: 57.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IK3_B_0LIB2_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	GLU A 305 MET A 309 LEU A 317 VAL A 318 HIS A 380 LEU A 389	P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) None P16 A 2 (-4.4A)	0.67A	3ik3B-1opkA: 34.6	3ik3B-1opkA: 57.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IK3_B_0LIB2_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 7	LEU A 267 LYS A 290 VAL A 308 ILE A 332	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) None P16 A 2 (-4.1A)	0.50A	3ik3B-1opkA: 34.6	3ik3B-1opkA: 57.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IK3_B_0LIB2_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 7	LEU A 267 VAL A 308 ILE A 332 MET A 337	P16 A 2 ( 4.2A) None P16 A 2 (-4.1A) None	0.35A	3ik3B-1opkA: 34.6	3ik3B-1opkA: 57.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3K54_A_1N1A1_1 (TYROSINE-PROTEIN KINASE BTK)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 ALA A 288 LYS A 290 GLU A 305 MET A 309 VAL A 318 ILE A 332 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.79A	3k54A-1opkA: 30.3	3k54A-1opkA: 29.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_A_STIA2_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	TYR A 272 VAL A 275 ALA A 288 GLU A 305 MET A 309 THR A 334 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.81A	3k5vA-1opkA: 37.0	3k5vA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_A_STIA2_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 THR A 334 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.71A	3k5vA-1opkA: 37.0	3k5vA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_A_STIA2_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	LEU A 267 LYS A 290 VAL A 308 VAL A 318 ILE A 332	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A)	0.52A	3k5vA-1opkA: 37.0	3k5vA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_A_STIA2_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 6	LEU A 267 VAL A 308 ILE A 332 MET A 337	P16 A 2 ( 4.2A) None P16 A 2 (-4.1A) None	0.45A	3k5vA-1opkA: 37.0	3k5vA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_B_STIB2_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	TYR A 272 VAL A 275 ALA A 288 GLU A 305 MET A 309 THR A 334 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.83A	3k5vB-1opkA: 37.2	3k5vB-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_B_STIB2_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 THR A 334 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.68A	3k5vB-1opkA: 37.2	3k5vB-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_B_STIB2_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	LEU A 267 LYS A 290 VAL A 308 VAL A 318 ILE A 332	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A)	0.50A	3k5vB-1opkA: 37.2	3k5vB-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_B_STIB2_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	LEU A 267 VAL A 308 VAL A 318 ILE A 332 MET A 337	P16 A 2 ( 4.2A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None	0.47A	3k5vB-1opkA: 37.2	3k5vB-1opkA: 58.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3LFA_A_1N1A361_1 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 8	ALA A 288 LYS A 290 GLU A 305 THR A 334 MET A 337	P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) None	0.45A	3lfaA-1opkA: 19.7	3lfaA-1opkA: 22.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MIY_A_B49A1_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 11	ALA A 288 VAL A 318 PHE A 336 MET A 337 GLY A 340 LEU A 389	P16 A 2 (-3.4A) P16 A 2 ( 4.7A) P16 A 2 ( 4.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.74A	3miyA-1opkA: 30.8	3miyA-1opkA: 26.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MIY_B_B49B2_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 9	ALA A 288 PHE A 336 MET A 337 GLY A 340 LEU A 389	P16 A 2 (-3.4A) P16 A 2 ( 4.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.59A	3miyB-1opkA: 31.0	3miyB-1opkA: 26.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 TYR A 272 VAL A 275 ALA A 288 GLU A 305 MET A 309 THR A 334 PHE A 336 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-4.4A)	0.79A	3ms9A-1opkA: 34.3	3ms9A-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 THR A 334 PHE A 336 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.76A	3ms9A-1opkA: 34.3	3ms9A-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_A_STIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	LYS A 290 VAL A 308 VAL A 318 ILE A 332 MET A 337	P16 A 2 (-4.5A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None	0.57A	3ms9A-1opkA: 34.3	3ms9A-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_A_STIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	LYS A 290 VAL A 318 ILE A 332 MET A 337 ARG A 381	P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None None	0.95A	3ms9A-1opkA: 34.3	3ms9A-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	11 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 THR A 334 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.74A	3ms9B-1opkA: 34.5	3ms9B-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_B_STIB1_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 7	LYS A 290 VAL A 308 VAL A 318 ILE A 332	P16 A 2 (-4.5A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A)	0.54A	3ms9B-1opkA: 34.5	3ms9B-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_B_STIB1_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 7	TYR A 272 VAL A 308 VAL A 318 ILE A 332 MET A 337	P16 A 2 (-3.6A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None	0.70A	3ms9B-1opkA: 34.5	3ms9B-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 TYR A 272 VAL A 275 ALA A 288 GLU A 305 MET A 309 THR A 334 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-4.4A)	0.76A	3mssA-1opkA: 34.5	3mssA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 THR A 334 PHE A 336 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.74A	3mssA-1opkA: 34.5	3mssA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_A_STIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 6	LYS A 290 VAL A 308 VAL A 318 ILE A 332	P16 A 2 (-4.5A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A)	0.47A	3mssA-1opkA: 34.5	3mssA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_A_STIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 6	LYS A 290 VAL A 318 ILE A 332 ARG A 381	P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None	0.97A	3mssA-1opkA: 34.5	3mssA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_A_STIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 6	VAL A 308 VAL A 318 ILE A 332 MET A 337	None P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None	0.46A	3mssA-1opkA: 34.5	3mssA-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	GLU A 305 MET A 309 ILE A 312 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.64A	3mssB-1opkA: 34.6	3mssB-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	GLU A 305 MET A 309 ILE A 312 THR A 334 GLY A 340 LEU A 389	P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.60A	3mssB-1opkA: 34.6	3mssB-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.68A	3mssB-1opkA: 34.6	3mssB-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 THR A 334 PHE A 336 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.63A	3mssB-1opkA: 34.6	3mssB-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_B_STIB1_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 7	TYR A 272 LYS A 290 VAL A 308 VAL A 318 ILE A 332	P16 A 2 (-3.6A) P16 A 2 (-4.5A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A)	0.90A	3mssB-1opkA: 34.6	3mssB-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_B_STIB1_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 7	TYR A 272 VAL A 308 VAL A 318 ILE A 332 MET A 337	P16 A 2 (-3.6A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None	0.73A	3mssB-1opkA: 34.6	3mssB-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_C_STIC1_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 TYR A 272 VAL A 275 ALA A 288 GLU A 305 MET A 309 THR A 334 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-4.4A)	0.78A	3mssC-1opkA: 34.5	3mssC-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_C_STIC1_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 THR A 334 PHE A 336 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.75A	3mssC-1opkA: 34.5	3mssC-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_C_STIC1_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 6	LYS A 290 VAL A 308 VAL A 318 ILE A 332	P16 A 2 (-4.5A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A)	0.48A	3mssC-1opkA: 34.5	3mssC-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_C_STIC1_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 6	LYS A 290 VAL A 318 ILE A 332 ARG A 381	P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None	1.00A	3mssC-1opkA: 34.5	3mssC-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_C_STIC1_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 6	VAL A 308 VAL A 318 ILE A 332 MET A 337	None P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None	0.48A	3mssC-1opkA: 34.5	3mssC-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_D_STID1_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 ALA A 288 GLU A 305 MET A 309 ILE A 312 THR A 334 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.79A	3mssD-1opkA: 34.6	3mssD-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_D_STID1_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 TYR A 272 ALA A 288 GLU A 305 MET A 309 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.6A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.84A	3mssD-1opkA: 34.6	3mssD-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_D_STID1_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	VAL A 275 LYS A 290 VAL A 308 VAL A 318 ILE A 332	P16 A 2 (-4.5A) P16 A 2 (-4.5A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A)	0.52A	3mssD-1opkA: 34.6	3mssD-1opkA: 58.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_D_STID1_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	VAL A 275 VAL A 308 VAL A 318 ILE A 332 MET A 337	P16 A 2 (-4.5A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None	0.50A	3mssD-1opkA: 34.6	3mssD-1opkA: 58.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OCT_A_1N1A663_1 (TYROSINE-PROTEIN KINASE BTK)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 MET A 309 VAL A 318 THR A 334 GLY A 340 GLU A 348 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) None P16 A 2 (-4.4A)	1.12A	3octA-1opkA: 32.5	3octA-1opkA: 28.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OEZ_A_STIA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	ALA A 288 GLU A 305 MET A 309 ILE A 312 THR A 334 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.57A	3oezA-1opkA: 31.3	3oezA-1opkA: 30.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OEZ_A_STIA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	ALA A 288 GLU A 305 MET A 309 ILE A 312 VAL A 318 THR A 334 GLY A 340 LEU A 389	P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.49A	3oezA-1opkA: 31.3	3oezA-1opkA: 30.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OEZ_A_STIA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 THR A 334 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.69A	3oezA-1opkA: 31.3	3oezA-1opkA: 30.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OEZ_A_STIA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 VAL A 318 THR A 334 GLY A 340 LEU A 389	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.63A	3oezA-1opkA: 31.3	3oezA-1opkA: 30.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OEZ_B_STIB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	ALA A 288 LYS A 290 GLU A 305 VAL A 308 MET A 309 ILE A 332 THR A 334 LEU A 389 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) None P16 A 2 (-3.3A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.66A	3oezB-1opkA: 31.4	3oezB-1opkA: 30.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OEZ_B_STIB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	VAL A 275 ALA A 288 LYS A 290 VAL A 308 MET A 309 ILE A 332 THR A 334 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) None P16 A 2 (-3.3A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.67A	3oezB-1opkA: 31.4	3oezB-1opkA: 30.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OND_A_ADNA506_2 (ADENOSYLHOMOCYSTEINA SE)	4crm	TRANSLATION INITIATION FACTOR RLI1 (Saccharomyces cerevisiae)	3 / 3	GLN P 127 THR P 118 LEU P 131	None ATP P1609 (-3.6A) None	0.75A	3ondA-4crmP: undetectable	3ondA-4crmP: 21.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OND_B_ADNB507_2 (ADENOSYLHOMOCYSTEINA SE)	4crm	TRANSLATION INITIATION FACTOR RLI1 (Saccharomyces cerevisiae)	3 / 3	GLN P 127 THR P 118 LEU P 131	None ATP P1609 (-3.6A) None	0.76A	3ondB-4crmP: undetectable	3ondB-4crmP: 21.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	ALA A 288 GLU A 305 MET A 309 ILE A 312 LEU A 317 THR A 334 GLY A 340 HIS A 380 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None None P16 A 2 (-3.7A) P16 A 2 (-3.4A) None P16 A 2 (-3.5A)	0.52A	3oxzA-1opkA: 34.6	3oxzA-1opkA: 57.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	ALA A 288 GLU A 305 MET A 309 ILE A 312 LEU A 317 VAL A 318 THR A 334 GLY A 340 HIS A 380	P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None None P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) None	0.50A	3oxzA-1opkA: 34.6	3oxzA-1opkA: 57.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 9	LEU A 267 LYS A 290 VAL A 308 ILE A 332 MET A 337 LEU A 389 VAL A 398	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) None P16 A 2 (-4.1A) None P16 A 2 (-4.4A) None	0.50A	3oxzA-1opkA: 34.6	3oxzA-1opkA: 57.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PYY_A_STIA3_1 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 THR A 334 PHE A 336	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 ( 4.4A)	0.53A	3pyyA-1opkA: 34.3	3pyyA-1opkA: 59.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PYY_A_STIA3_1 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 THR A 334 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.67A	3pyyA-1opkA: 34.3	3pyyA-1opkA: 59.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PYY_A_STIA3_2 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 6	LYS A 290 VAL A 318 ILE A 332 ARG A 381	P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) None	1.02A	3pyyA-1opkA: 34.3	3pyyA-1opkA: 59.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PYY_A_STIA3_2 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	TYR A 272 LYS A 290 VAL A 308 VAL A 318 ILE A 332	P16 A 2 (-3.6A) P16 A 2 (-4.5A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A)	0.92A	3pyyA-1opkA: 34.3	3pyyA-1opkA: 59.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PYY_B_STIB4_1 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 TYR A 272 VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 VAL A 318 THR A 334 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-4.4A)	0.77A	3pyyB-1opkA: 34.6	3pyyB-1opkA: 59.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PYY_B_STIB4_1 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 VAL A 318 THR A 334 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.59A	3pyyB-1opkA: 34.6	3pyyB-1opkA: 59.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PYY_B_STIB4_2 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 5	LYS A 290 VAL A 308 ILE A 332 MET A 337 ARG A 381	P16 A 2 (-4.5A) None P16 A 2 (-4.1A) None None	0.93A	3pyyB-1opkA: 34.6	3pyyB-1opkA: 59.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3QLG_A_1N1A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	11 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 VAL A 318 THR A 334 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.81A	3qlgA-1opkA: 31.7	3qlgA-1opkA: 30.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3QLG_B_1N1B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 VAL A 318 THR A 334 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.76A	3qlgB-1opkA: 32.0	3qlgB-1opkA: 30.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3SXR_A_1N1A1_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 VAL A 275 ALA A 288 MET A 309 VAL A 318 ILE A 332 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.62A	3sxrA-1opkA: 33.1	3sxrA-1opkA: 25.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3SXR_B_1N1B2_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 VAL A 275 ALA A 288 MET A 309 VAL A 318 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.58A	3sxrB-1opkA: 32.9	3sxrB-1opkA: 25.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UE4_A_DB8A601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 ALA A 288 GLU A 305 THR A 334 PHE A 336 MET A 337 GLY A 340 LEU A 389 PHE A 401	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A) None	0.95A	3ue4A-1opkA: 37.4	3ue4A-1opkA: 57.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UE4_A_DB8A601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 ALA A 288 LYS A 290 GLU A 305 ILE A 332 THR A 334 PHE A 336 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.73A	3ue4A-1opkA: 37.4	3ue4A-1opkA: 57.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UE4_A_DB8A601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 ALA A 288 LYS A 290 VAL A 318 ILE A 332 THR A 334 PHE A 336 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.65A	3ue4A-1opkA: 37.4	3ue4A-1opkA: 57.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UE4_A_DB8A601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 ALA A 288 VAL A 318 THR A 334 PHE A 336 MET A 337 GLY A 340 LEU A 389 PHE A 401	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A) None	0.78A	3ue4A-1opkA: 37.4	3ue4A-1opkA: 57.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UE4_B_DB8B601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	11 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 VAL A 318 ILE A 332 THR A 334 PHE A 336 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.67A	3ue4B-1opkA: 37.8	3ue4B-1opkA: 57.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UE4_B_DB8B601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	11 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 VAL A 318 THR A 334 PHE A 336 GLY A 340 LEU A 389 PHE A 401	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) None	0.89A	3ue4B-1opkA: 37.8	3ue4B-1opkA: 57.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UG2_A_IREA1_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 MET A 337 GLY A 340 ASP A 344 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) None P16 A 2 (-3.4A) None P16 A 2 (-4.4A)	0.81A	3ug2A-1opkA: 31.8	3ug2A-1opkA: 25.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WZD_A_LEVA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 12	LEU A 267 GLY A 268 VAL A 275 ALA A 288 GLY A 340	P16 A 2 ( 4.2A) P16 A 2 ( 4.3A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-3.4A)	0.40A	3wzdA-1opkA: 30.6	3wzdA-1opkA: 25.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WZD_A_LEVA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 GLY A 340	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.4A)	0.37A	3wzdA-1opkA: 30.6	3wzdA-1opkA: 25.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WZE_A_BAXA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 PHE A 336 GLY A 340 LEU A 373 HIS A 380	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) None None	0.44A	3wzeA-1opkA: 30.3	3wzeA-1opkA: 25.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WZE_A_BAXA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 PHE A 336 GLY A 340 HIS A 380	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) None	0.54A	3wzeA-1opkA: 30.3	3wzeA-1opkA: 25.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ZOS_A_0LIA1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 ALA A 288 LYS A 290 GLU A 305 THR A 334 LEU A 373 HIS A 380 ARG A 381 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) None None None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.90A	3zosA-1opkA: 29.5	3zosA-1opkA: 26.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ZOS_B_0LIB1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	ALA A 288 LYS A 290 GLU A 305 THR A 334 LEU A 373 HIS A 380 ARG A 381 LEU A 389 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) None None None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.92A	3zosB-1opkA: 29.4	3zosB-1opkA: 26.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AG8_A_AXIA2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 VAL A 318 PHE A 336 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 ( 4.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.44A	4ag8A-1opkA: 30.7	4ag8A-1opkA: 26.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.47A	4agcA-1opkA: 30.2	4agcA-1opkA: 28.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AGD_A_B49A2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 11	LEU A 267 ALA A 288 VAL A 318 PHE A 336 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 ( 4.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.35A	4agdA-1opkA: 29.8	4agdA-1opkA: 28.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ANQ_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 9	LEU A 267 VAL A 275 ALA A 288 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.56A	4anqA-1opkA: 30.6	4anqA-1opkA: 27.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ANS_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 9	LEU A 267 VAL A 275 ALA A 288 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.57A	4ansA-1opkA: 30.5	4ansA-1opkA: 27.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ASD_A_BAXA1500_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 PHE A 336 GLY A 340 LEU A 373 HIS A 380	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) None None	0.62A	4asdA-1opkA: 30.0	4asdA-1opkA: 28.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4BKJ_A_STIA1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 THR A 334 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.93A	4bkjA-1opkA: 28.8	4bkjA-1opkA: 26.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4BKJ_B_STIB1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 THR A 334 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.80A	4bkjB-1opkA: 28.8	4bkjB-1opkA: 26.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4C8B_A_0LIA1000_1 (RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	ALA A 288 LYS A 290 GLU A 305 ILE A 332 THR A 334 HIS A 380 LEU A 389 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.50A	4c8bA-1opkA: 25.4	4c8bA-1opkA: 20.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4C8B_B_0LIB1000_1 (RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	ALA A 288 LYS A 290 GLU A 305 THR A 334 HIS A 380 LEU A 389 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.47A	4c8bB-1opkA: 25.6	4c8bB-1opkA: 20.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4CSV_A_STIA1265_1 (SRC-ABL TYROSINE KINASE ANCESTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 THR A 334 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.65A	4csvA-1opkA: 32.5	4csvA-1opkA: 47.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4CSV_A_STIA1265_1 (SRC-ABL TYROSINE KINASE ANCESTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 VAL A 318 THR A 334 LEU A 389	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-4.4A)	0.63A	4csvA-1opkA: 32.5	4csvA-1opkA: 47.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4CSV_A_STIA1265_2 (SRC-ABL TYROSINE KINASE ANCESTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 4	LYS A 290 ILE A 332 MET A 337 PHE A 378	P16 A 2 (-4.5A) P16 A 2 (-4.1A) None None	0.63A	4csvA-1opkA: 32.2	4csvA-1opkA: 47.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4HJO_A_AQ4A1001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 THR A 334 MET A 337 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.7A) None P16 A 2 (-4.4A)	0.67A	4hjoA-1opkA: 29.7	4hjoA-1opkA: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4HJO_A_AQ4A1001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	LEU A 267 VAL A 275 ALA A 288 THR A 334 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-3.7A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.63A	4hjoA-1opkA: 29.7	4hjoA-1opkA: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MKC_A_4MKA1503_1 (ALK TYROSINE KINASE RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	LEU A 267 GLY A 273 VAL A 275 ALA A 288 LYS A 290 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) None P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.87A	4mkcA-1opkA: 30.9	4mkcA-1opkA: 28.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXO_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 VAL A 318 ILE A 332 THR A 334	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A)	0.72A	4mxoA-1opkA: 32.1	4mxoA-1opkA: 30.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXO_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 MET A 309 VAL A 318 ILE A 332 THR A 334 GLY A 340	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A)	0.86A	4mxoA-1opkA: 32.1	4mxoA-1opkA: 30.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXO_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 VAL A 318 ILE A 332 THR A 334	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A)	0.70A	4mxoB-1opkA: 32.1	4mxoB-1opkA: 30.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXO_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 VAL A 318 ILE A 332 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.73A	4mxoB-1opkA: 32.1	4mxoB-1opkA: 30.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXX_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	ALA A 288 LYS A 290 GLU A 305 MET A 309 VAL A 318 THR A 334 GLY A 340 LEU A 389	P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.88A	4mxxA-1opkA: 32.1	4mxxA-1opkA: 30.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXX_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	ALA A 288 LYS A 290 GLU A 305 VAL A 318 ILE A 332 THR A 334 GLY A 340 LEU A 389	P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.78A	4mxxA-1opkA: 32.1	4mxxA-1opkA: 30.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXX_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 ALA A 288 LYS A 290 GLU A 305 ILE A 332 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.93A	4mxxA-1opkA: 32.1	4mxxA-1opkA: 30.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXX_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 ALA A 288 LYS A 290 GLU A 305 MET A 309 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	1.04A	4mxxA-1opkA: 32.1	4mxxA-1opkA: 30.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXX_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 VAL A 318 THR A 334 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.78A	4mxxB-1opkA: 31.6	4mxxB-1opkA: 30.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXY_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 VAL A 318 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.96A	4mxyB-1opkA: 32.1	4mxyB-1opkA: 29.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXZ_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 VAL A 318 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.96A	4mxzB-1opkA: 32.1	4mxzB-1opkA: 29.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OTW_A_DB8A1101_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	LEU A 267 VAL A 275 LYS A 290 VAL A 318 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.90A	4otwA-1opkA: 28.5	4otwA-1opkA: 24.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OTW_A_DB8A1101_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	LEU A 267 VAL A 275 LYS A 290 VAL A 318 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.74A	4otwA-1opkA: 28.5	4otwA-1opkA: 24.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QMN_A_DB8A401_1 (SERINE/THREONINE-PRO TEIN KINASE 24)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	ALA A 288 LYS A 290 GLU A 305 ILE A 332 LEU A 389 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-4.1A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.80A	4qmnA-1opkA: 26.0	4qmnA-1opkA: 22.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QRC_A_0LIA802_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	ALA A 288 GLU A 305 MET A 309 LEU A 373 ARG A 381 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None None P16 A 2 (-3.5A)	0.83A	4qrcA-1opkA: 30.7	4qrcA-1opkA: 29.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QRC_A_0LIA802_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 8	LEU A 267 VAL A 275 LYS A 290 HIS A 380 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-4.5A) None P16 A 2 (-4.4A)	0.48A	4qrcA-1opkA: 30.7	4qrcA-1opkA: 29.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4R7I_A_STIA1001_1 (MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 THR A 334 LEU A 389	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-4.4A)	0.45A	4r7iA-1opkA: 30.3	4r7iA-1opkA: 26.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RJD_B_TFPB204_1 (CALMODULIN)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 8	LEU A 395 GLY A 391 GLU A 392 ALA A 288	None GOL A 3 (-4.9A) GOL A 3 (-4.5A) P16 A 2 (-3.4A)	0.88A	4rjdA-1opkA: 0.0 4rjdB-1opkA: 0.0	4rjdA-1opkA: 12.43 4rjdB-1opkA: 12.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_A_AXIA601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 PHE A 336 MET A 337 GLY A 340 ASN A 387 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 ( 4.4A) None P16 A 2 (-3.4A) None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.50A	4twpA-1opkA: 37.7	4twpA-1opkA: 98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_A_AXIA601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	TYR A 272 VAL A 275 ALA A 288 LYS A 290 PHE A 336 MET A 337 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 ( 4.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.91A	4twpA-1opkA: 37.7	4twpA-1opkA: 98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_B_AXIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 TYR A 272 VAL A 275 ALA A 288 LYS A 290 PHE A 336 MET A 337 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 ( 4.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.80A	4twpB-1opkA: 38.4	4twpB-1opkA: 98.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_B_AXIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 PHE A 336 MET A 337 GLY A 340 ASN A 387 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 ( 4.4A) None P16 A 2 (-3.4A) None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.51A	4twpB-1opkA: 38.4	4twpB-1opkA: 98.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4TYJ_A_0LIA801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	ALA A 288 GLU A 305 MET A 309 ILE A 312 HIS A 380 LEU A 389 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.64A	4tyjA-1opkA: 30.8	4tyjA-1opkA: 28.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4U0I_A_0LIA1001_2 (MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	ALA A 288 LYS A 290 THR A 334 GLY A 340 HIS A 380 LEU A 389	P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) None P16 A 2 (-4.4A)	0.47A	4u0iA-1opkA: 30.5	4u0iA-1opkA: 24.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 11	LEU A 267 VAL A 275 ALA A 288 MET A 337 GLY A 340 ASN A 387 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) None P16 A 2 (-3.4A) None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.64A	4u5jA-1opkA: 33.6	4u5jA-1opkA: 30.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 9	LEU A 267 VAL A 275 ALA A 288 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.48A	4u5jB-1opkA: 32.9	4u5jB-1opkA: 30.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4UXQ_A_0LIA1752_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	ALA A 288 GLU A 305 ILE A 312 LEU A 373 HIS A 380 LEU A 389	P16 A 2 (-3.4A) P16 A 2 (-4.2A) None None None P16 A 2 (-4.4A)	0.85A	4uxqA-1opkA: 30.4	4uxqA-1opkA: 28.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4UXQ_A_0LIA1752_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	LEU A 267 ALA A 288 GLU A 305 LEU A 373 HIS A 380 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) None None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.66A	4uxqA-1opkA: 30.4	4uxqA-1opkA: 28.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4V01_A_0LIA1776_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	ALA A 288 GLU A 305 MET A 309 ILE A 312 LEU A 373 HIS A 380 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None None None P16 A 2 (-3.5A)	0.85A	4v01A-1opkA: 29.9	4v01A-1opkA: 27.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4V01_B_0LIB1770_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	ALA A 288 GLU A 305 MET A 309 LEU A 373 HIS A 380 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None None P16 A 2 (-3.5A)	0.59A	4v01B-1opkA: 30.1	4v01B-1opkA: 27.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4V04_A_0LIA1772_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	VAL A 275 ALA A 288 GLU A 305 HIS A 380 ALA A 399 GLY A 402	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) None P16 A 2 (-3.5A) None	1.08A	4v04A-1opkA: 29.6	4v04A-1opkA: 27.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4V04_A_0LIA1772_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	VAL A 275 ALA A 288 GLU A 305 LEU A 373 HIS A 380 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) None None P16 A 2 (-3.5A)	0.63A	4v04A-1opkA: 29.6	4v04A-1opkA: 27.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4V04_B_0LIB1771_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 12	ALA A 288 GLU A 305 LEU A 373 HIS A 380 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-4.2A) None None P16 A 2 (-3.5A)	0.63A	4v04B-1opkA: 29.8	4v04B-1opkA: 27.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_A_AXIA9000_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 11	ALA A 288 THR A 334 MET A 337 GLY A 340 ASN A 387 LEU A 389 ALA A 399	P16 A 2 (-3.4A) P16 A 2 (-3.7A) None P16 A 2 (-3.4A) None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.52A	4wa9A-1opkA: 33.1	4wa9A-1opkA: 57.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_A_AXIA9000_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 11	LEU A 267 ALA A 288 LYS A 290 THR A 334 MET A 337 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.7A) None P16 A 2 (-4.4A)	1.01A	4wa9A-1opkA: 33.1	4wa9A-1opkA: 57.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_A_AXIA9000_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 11	LEU A 267 ALA A 288 THR A 334 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-3.7A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.84A	4wa9A-1opkA: 33.1	4wa9A-1opkA: 57.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_A_AXIA9000_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 11	TYR A 272 ALA A 288 THR A 334 MET A 337 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-3.6A) P16 A 2 (-3.4A) P16 A 2 (-3.7A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.85A	4wa9A-1opkA: 33.1	4wa9A-1opkA: 57.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_B_AXIB9000_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	TYR A 272 VAL A 275 ALA A 288 THR A 334 MET A 337 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-3.7A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.79A	4wa9B-1opkA: 37.8	4wa9B-1opkA: 57.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_B_AXIB9000_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	VAL A 275 ALA A 288 LYS A 290 THR A 334 PHE A 336 MET A 337 GLY A 340 ASN A 387 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) None P16 A 2 (-3.4A) None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.54A	4wa9B-1opkA: 37.8	4wa9B-1opkA: 57.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WBO_C_ANWC601_0 (RHODOPSIN KINASE)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 6	LEU A 267 ALA A 288 MET A 337 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) None P16 A 2 (-4.4A)	0.50A	4wboC-1opkA: 22.0	4wboC-1opkA: 26.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WKQ_A_IREA1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	LEU A 267 ALA A 288 GLU A 305 THR A 334 GLY A 340 ASP A 344 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) None P16 A 2 (-4.4A)	0.88A	4wkqA-1opkA: 32.1	4wkqA-1opkA: 24.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WKQ_A_IREA1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 ALA A 288 LYS A 290 GLU A 305 MET A 309 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.76A	4wkqA-1opkA: 32.1	4wkqA-1opkA: 24.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XEY_A_1N1A601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	12 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 MET A 309 VAL A 318 ILE A 332 THR A 334 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.63A	4xeyA-1opkA: 37.1	4xeyA-1opkA: 80.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XEY_B_1N1B601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 VAL A 318 ILE A 332 THR A 334 PHE A 336 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-4.4A)	0.60A	4xeyB-1opkA: 36.3	4xeyB-1opkA: 80.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XEY_B_1N1B601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 VAL A 275 ALA A 288 VAL A 318 ILE A 332 THR A 334 PHE A 336 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.62A	4xeyB-1opkA: 36.3	4xeyB-1opkA: 80.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XEY_B_1N1B601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	VAL A 275 ALA A 288 LYS A 290 MET A 309 VAL A 318 ILE A 332 THR A 334 PHE A 336 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.52A	4xeyB-1opkA: 36.3	4xeyB-1opkA: 80.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XEY_B_1N1B601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	VAL A 275 ALA A 288 MET A 309 VAL A 318 ILE A 332 THR A 334 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.47A	4xeyB-1opkA: 36.3	4xeyB-1opkA: 80.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_A_1N1A601_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	11 / 12	LEU A 267 ALA A 288 LYS A 290 GLU A 305 MET A 309 VAL A 318 THR A 334 MET A 337 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.72A	4xliA-1opkA: 36.5	4xliA-1opkA: 92.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_B_1N1B600_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	11 / 12	LEU A 267 ALA A 288 LYS A 290 GLU A 305 MET A 309 VAL A 318 ILE A 332 THR A 334 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.68A	4xliB-1opkA: 36.7	4xliB-1opkA: 92.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ZAU_A_YY3A1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 8	LEU A 267 VAL A 275 ALA A 288 MET A 337 GLY A 340	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) None P16 A 2 (-3.4A)	0.59A	4zauA-1opkA: 31.9	4zauA-1opkA: 24.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AAA_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 9	LEU A 267 VAL A 275 ALA A 288 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.56A	5aaaA-1opkA: 31.0	5aaaA-1opkA: 26.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AAB_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 10	LEU A 267 VAL A 275 ALA A 288 LYS A 290 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.65A	5aabA-1opkA: 31.0	5aabA-1opkA: 26.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AAC_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 10	LEU A 267 VAL A 275 ALA A 288 LYS A 290 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.74A	5aacA-1opkA: 30.9	5aacA-1opkA: 25.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_A_DB8A800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	LEU A 267 ALA A 288 LYS A 290 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	1.04A	5ajqA-1opkA: 22.7	5ajqA-1opkA: 19.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_A_DB8A800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	LEU A 267 GLY A 268 ALA A 288 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 ( 4.3A) P16 A 2 (-3.4A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.98A	5ajqA-1opkA: 22.7	5ajqA-1opkA: 19.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_B_DB8B800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 10	ALA A 288 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-3.4A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.68A	5ajqB-1opkA: 23.0	5ajqB-1opkA: 19.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5BVW_A_1N1A1009_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 THR A 334 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.59A	5bvwA-1opkA: 29.8	5bvwA-1opkA: 26.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_A_1N1A501_1 (PROTEIN-TYROSINE KINASE 6)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	LEU A 267 VAL A 275 ALA A 288 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.74A	5h2uA-1opkA: 29.5	5h2uA-1opkA: 25.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_B_1N1B501_1 (PROTEIN-TYROSINE KINASE 6)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	LEU A 267 VAL A 275 ALA A 288 ILE A 332 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.78A	5h2uB-1opkA: 29.5	5h2uB-1opkA: 25.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_C_1N1C501_1 (PROTEIN-TYROSINE KINASE 6)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	LEU A 267 ALA A 288 ILE A 332 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.75A	5h2uC-1opkA: 29.3	5h2uC-1opkA: 25.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_A_032A401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 12	GLY A 268 VAL A 275 ALA A 288 ILE A 332 THR A 334	P16 A 2 ( 4.3A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.1A) P16 A 2 (-3.7A)	0.69A	5hesA-1opkA: 10.6	5hesA-1opkA: 20.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_B_032B401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	GLY A 268 ALA A 288 LYS A 290 ILE A 332 THR A 334 ASP A 344	P16 A 2 ( 4.3A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) None	1.00A	5hesB-1opkA: 27.3	5hesB-1opkA: 20.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_B_032B401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	GLY A 268 VAL A 275 ALA A 288 LYS A 290 ILE A 332 THR A 334	P16 A 2 ( 4.3A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.1A) P16 A 2 (-3.7A)	0.67A	5hesB-1opkA: 27.3	5hesB-1opkA: 20.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_B_032B401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	GLY A 269 VAL A 275 ALA A 288 LYS A 290 ILE A 332 THR A 334	None P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.1A) P16 A 2 (-3.7A)	0.76A	5hesB-1opkA: 27.3	5hesB-1opkA: 20.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HI2_A_BAXA801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	ALA A 288 LYS A 290 GLU A 305 THR A 334 LEU A 373 HIS A 380	P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) None None	0.55A	5hi2A-1opkA: 26.4	5hi2A-1opkA: 19.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 12	VAL A 275 ALA A 288 LYS A 290 ILE A 332 THR A 334	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.1A) P16 A 2 (-3.7A)	0.40A	5hieA-1opkA: 25.4	5hieA-1opkA: 21.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 12	VAL A 275 ALA A 288 LYS A 290 ILE A 332 THR A 334	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.1A) P16 A 2 (-3.7A)	0.40A	5hieB-1opkA: 25.4	5hieB-1opkA: 21.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 12	VAL A 275 ALA A 288 LYS A 290 ILE A 332 THR A 334	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.1A) P16 A 2 (-3.7A)	0.40A	5hieD-1opkA: 25.5	5hieD-1opkA: 21.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5I9X_A_DB8A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	ALA A 288 LYS A 290 ILE A 332 THR A 334 GLY A 340 GLU A 348 LEU A 389	P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) None P16 A 2 (-4.4A)	0.74A	5i9xA-1opkA: 31.6	5i9xA-1opkA: 25.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5I9Y_A_1N1A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	ALA A 288 LYS A 290 MET A 309 THR A 334 GLY A 340 GLU A 348 LEU A 389	P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) None P16 A 2 (-4.4A)	0.83A	5i9yA-1opkA: 31.0	5i9yA-1opkA: 25.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5MO4_A_NILA601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 10	LEU A 267 TYR A 272 VAL A 275 GLU A 305 ILE A 332 MET A 337 GLY A 340	P16 A 2 ( 4.2A) P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-4.1A) None P16 A 2 (-3.4A)	0.74A	5mo4A-1opkA: 54.2	5mo4A-1opkA: 98.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5MO4_A_NILA601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 10	LEU A 267 VAL A 275 LYS A 290 GLU A 305 ILE A 332 PHE A 336 MET A 337 GLY A 340	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-4.1A) P16 A 2 ( 4.4A) None P16 A 2 (-3.4A)	0.58A	5mo4A-1opkA: 54.2	5mo4A-1opkA: 98.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5MO4_A_NILA601_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	ALA A 288 VAL A 308 MET A 309 ILE A 312 LEU A 317 HIS A 380 LEU A 389	P16 A 2 (-3.4A) None P16 A 2 (-3.3A) None None None P16 A 2 (-4.4A)	0.62A	5mo4A-1opkA: 54.2	5mo4A-1opkA: 98.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5MO4_A_NILA601_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	ALA A 288 VAL A 308 MET A 309 LEU A 317 HIS A 380 LEU A 389 ALA A 399	P16 A 2 (-3.4A) None P16 A 2 (-3.3A) None None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.59A	5mo4A-1opkA: 54.2	5mo4A-1opkA: 98.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5MO4_A_NILA601_2 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	ALA A 288 VAL A 308 MET A 309 LEU A 317 VAL A 318 HIS A 380 LEU A 389	P16 A 2 (-3.4A) None P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) None P16 A 2 (-4.4A)	0.58A	5mo4A-1opkA: 54.2	5mo4A-1opkA: 98.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	GLY A 273 VAL A 275 ALA A 288 LYS A 290 ILE A 332 THR A 334	None P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.1A) P16 A 2 (-3.7A)	0.83A	5p9iA-1opkA: 30.0	5p9iA-1opkA: 28.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5TE0_A_XINA401_1 (AP2-ASSOCIATED PROTEIN KINASE 1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	ALA A 288 GLU A 305 MET A 309 VAL A 318 PHE A 336 GLY A 340 LEU A 389	P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.43A	5te0A-1opkA: 23.3	5te0A-1opkA: 19.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCV_A_1N1A404_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	LEU A 267 ALA A 288 LYS A 290 GLU A 305 VAL A 318 GLY A 340	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 ( 4.7A) P16 A 2 (-3.4A)	1.07A	5vcvA-1opkA: 22.9	5vcvA-1opkA: 21.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCV_A_1N1A404_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	LEU A 267 ALA A 288 LYS A 290 GLU A 305 VAL A 318 THR A 334	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A)	0.51A	5vcvA-1opkA: 22.9	5vcvA-1opkA: 21.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCY_A_DB8A401_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	6 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 THR A 334	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.7A)	0.59A	5vcyA-1opkA: 22.8	5vcyA-1opkA: 21.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.65A	5y7zA-1opkA: 22.7	5y7zA-1opkA: 10.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.65A	5y7zA-1opkA: 22.7	5y7zA-1opkA: 22.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y80_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.51A	5y80A-1opkA: 22.8	5y80A-1opkA: 10.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_A_LEVA801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	8 / 12	LEU A 267 GLY A 268 VAL A 275 ALA A 288 GLU A 305 MET A 309 GLY A 340 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 ( 4.3A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.4A) P16 A 2 (-3.5A)	0.50A	5zv2A-1opkA: 31.5	5zv2A-1opkA: 10.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_B_LEVB801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	LEU A 267 GLY A 268 VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 GLY A 340 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 ( 4.3A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.4A) P16 A 2 (-3.5A)	0.50A	5zv2B-1opkA: 31.3	5zv2B-1opkA: 10.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6BQG_A_ERMA1201_1 (5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562)	4crm	TRANSLATION INITIATION FACTOR RLI1 (Saccharomyces cerevisiae)	5 / 12	SER P 249 VAL P 524 GLY P 224 ASN P 387 VAL P 254	None None None ADP P1612 (-3.6A) None	1.10A	6bqgA-4crmP: undetectable	6bqgA-4crmP: 9.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6BSD_A_1N1A901_0 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	9 / 12	VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 THR A 334 MET A 337 GLY A 340 LEU A 389	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 (-3.7A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.53A	6bsdA-1opkA: 29.6	6bsdA-1opkA: 11.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6F3N_B_ADNB505_2 (-)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 4	GLN A 319 THR A 334 HIS A 380 LEU A 403	None P16 A 2 (-3.7A) None None	1.28A	6f3nB-1opkA: undetectable	6f3nB-1opkA: 23.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6FNM_A_1N1A1001_1 (-)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	VAL A 275 ALA A 288 ILE A 332 THR A 334 MET A 337 GLY A 340 LEU A 389	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.72A	6fnmA-1opkA: 32.3	6fnmA-1opkA: 27.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6FNM_A_1N1A1001_1 (-)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	7 / 12	VAL A 275 ALA A 288 LYS A 290 GLU A 305 ILE A 332 THR A 334 MET A 337	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) None	0.81A	6fnmA-1opkA: 32.3	6fnmA-1opkA: 27.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6GBN_A_ADNA501_2 (-)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 5	GLN A 319 THR A 334 HIS A 380 LEU A 403	None P16 A 2 (-3.7A) None None	1.29A	6gbnA-1opkA: undetectable	6gbnA-1opkA: 21.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6GBN_D_ADND501_2 (-)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 5	GLN A 319 THR A 334 HIS A 380 LEU A 403	None P16 A 2 (-3.7A) None None	1.28A	6gbnD-1opkA: undetectable	6gbnD-1opkA: 21.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD4_A_STIA604_0 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	11 / 12	VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 ILE A 312 VAL A 318 ILE A 332 THR A 334 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.70A	6hd4A-1opkA: 36.8	6hd4A-1opkA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD4_A_STIA604_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 5	TYR A 272 VAL A 308 MET A 337 GLY A 340	P16 A 2 (-3.6A) None None P16 A 2 (-3.4A)	0.76A	6hd4A-1opkA: 36.8	6hd4A-1opkA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD4_A_STIA604_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 5	VAL A 308 PHE A 336 MET A 337 GLY A 340	None P16 A 2 ( 4.4A) None P16 A 2 (-3.4A)	0.47A	6hd4A-1opkA: 36.8	6hd4A-1opkA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD4_B_STIB602_0 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 VAL A 318 ILE A 332 THR A 334 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.64A	6hd4B-1opkA: 36.9	6hd4B-1opkA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD4_B_STIB602_0 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 ILE A 312 VAL A 318 ILE A 332 THR A 334 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 (-3.5A)	0.70A	6hd4B-1opkA: 36.9	6hd4B-1opkA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD4_B_STIB602_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	LEU A 267 TYR A 272 VAL A 308 MET A 337 GLY A 340	P16 A 2 ( 4.2A) P16 A 2 (-3.6A) None None P16 A 2 (-3.4A)	0.84A	6hd4B-1opkA: 36.9	6hd4B-1opkA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD4_B_STIB602_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 6	LEU A 267 VAL A 308 PHE A 336 MET A 337 GLY A 340	P16 A 2 ( 4.2A) None P16 A 2 ( 4.4A) None P16 A 2 (-3.4A)	0.56A	6hd4B-1opkA: 36.9	6hd4B-1opkA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD6_A_STIA603_0 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	11 / 12	VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 VAL A 318 ILE A 332 THR A 334 PHE A 336 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) P16 A 2 ( 4.7A) P16 A 2 (-4.1A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.63A	6hd6A-1opkA: 36.7	6hd6A-1opkA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD6_A_STIA603_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	4 / 5	LEU A 267 ILE A 312 MET A 337 GLY A 340	P16 A 2 ( 4.2A) None None P16 A 2 (-3.4A)	0.86A	6hd6A-1opkA: 36.7	6hd6A-1opkA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD6_B_STIB601_0 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 GLU A 305 MET A 309 ILE A 312 VAL A 318 THR A 334 PHE A 336 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-4.4A)	0.68A	6hd6B-1opkA: 36.8	6hd6B-1opkA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD6_B_STIB601_0 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	10 / 12	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 MET A 309 ILE A 312 VAL A 318 THR A 334 PHE A 336	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.3A) None P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A)	0.60A	6hd6B-1opkA: 36.8	6hd6B-1opkA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD6_B_STIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 7	TYR A 272 VAL A 308 ILE A 332 MET A 337 GLY A 340	P16 A 2 (-3.6A) None P16 A 2 (-4.1A) None P16 A 2 (-3.4A)	0.75A	6hd6B-1opkA: 36.8	6hd6B-1opkA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD6_B_STIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	5 / 7	VAL A 308 ILE A 332 MET A 337 GLY A 340 ALA A 399	None P16 A 2 (-4.1A) None P16 A 2 (-3.4A) P16 A 2 (-3.5A)	0.58A	6hd6B-1opkA: 36.8	6hd6B-1opkA: 28.37

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1IEP_A_STIA201_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;TYR A 272;VAL A 275;ALA A 288;GLU A 305;MET A 309;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.83A","1iepA-1opkA:34.6",null],["1IEP_A_STIA201_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;THR A 334;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.70A","1iepA-1opkA:34.6","1iepA-1opkA:58.99"],["1IEP_A_STIA201_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LYS A 290;VAL A 308;VAL A 318;ILE A 332","P16 A   2 (-4.5A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A)","0.60A","1iepA-1opkA:34.6","1iepA-1opkA:58.99"],["1IEP_A_STIA201_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"VAL A 308;VAL A 318;ILE A 332;MET A 337","None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None","0.50A","1iepA-1opkA:34.6","1iepA-1opkA:58.99"],["1IEP_B_STIB202_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;TYR A 272;VAL A 275;ALA A 288;GLU A 305;MET A 309;THR A 334;GLY A 340","P16 A   2 ( 4.2A);P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-3.4A)","0.77A","1iepB-1opkA:34.7","1iepA-1opkA:58.99"],["1IEP_B_STIB202_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;THR A 334;PHE A 336;GLY A 340;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-3.5A)","0.78A","1iepB-1opkA:34.7","1iepB-1opkA:58.99"],["1IEP_B_STIB202_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LYS A 290;VAL A 308;VAL A 318;ILE A 332;MET A 337;LEU A 389","P16 A   2 (-4.5A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None;P16 A   2 (-4.4A)","0.65A","1iepB-1opkA:34.7","1iepB-1opkA:58.99"],["1IEP_B_STIB202_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"VAL A 318;ILE A 332;MET A 337;ARG A 381","P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None;None","0.94A","1iepB-1opkA:34.7","1iepB-1opkA:58.99"],["1JLF_A_NVPA999_1","HIV-1 RT A-CHAIN;HIV-1 RT B-CHAIN","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LEU A 346;VAL A 390;CYH A 388;GLY A 340","None;None;None;P16 A   2 (-3.4A)","1.05A","1jlfA-1opkA:2.2;1jlfB-1opkA:1.9","1iepB-1opkA:58.99"],["1M17_A_AQ4A999_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;THR A 334;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.70A","1m17A-1opkA:31.9","1jlfA-1opkA:21.60;1jlfB-1opkA:21.58"],["1ONI_A_BEZA502_0","14.5 KDA TRANSLATIONAL INHIBITOR PROTEIN","4crm","TRANSLATION INITIATION FACTOR RLI1","Saccharomyces cerevisiae",4,"ASN P   5;ASN P  74;ILE P  56;GLY P  57","None;None;None;SF4 P1610 ( 4.9A)","0.95A","1oniA-4crmP:undetectable;1oniB-4crmP:undetectable","1m17A-1opkA:25.09"],["1ONI_D_BEZD508_0","14.5 KDA TRANSLATIONAL INHIBITOR PROTEIN","4crm","TRANSLATION INITIATION FACTOR RLI1","Saccharomyces cerevisiae",4,"ASN P   5;ASN P  74;ILE P  56;GLY P  57","None;None;None;SF4 P1610 ( 4.9A)","0.95A","1oniD-4crmP:undetectable;1oniF-4crmP:undetectable","1oniA-4crmP:14.11;1oniB-4crmP:14.11"],["1OPJ_A_STIA3_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"GLU A 305;MET A 309;ILE A 312;VAL A 318;THR A 334;LEU A 389;ALA A 399","P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.67A","1opjA-1opkA:37.3","1oniD-4crmP:14.11;1oniF-4crmP:14.11"],["1OPJ_A_STIA3_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;VAL A 318;THR A 334;PHE A 336;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.60A","1opjA-1opkA:37.3","1opjA-1opkA:58.99"],["1OPJ_A_STIA3_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LYS A 290;VAL A 308;ILE A 332;MET A 337","P16 A   2 (-4.5A);None;P16 A   2 (-4.1A);None","0.55A","1opjA-1opkA:37.3","1opjA-1opkA:58.99"],["1OPJ_A_STIA3_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"TYR A 272;VAL A 308;ILE A 332;MET A 337","P16 A   2 (-3.6A);None;P16 A   2 (-4.1A);None","0.75A","1opjA-1opkA:37.3","1opjA-1opkA:58.99"],["1OPJ_B_STIB4_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"TYR A 272;VAL A 275;ALA A 288;GLU A 305;MET A 309;VAL A 318;THR A 334;GLY A 340","P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-3.4A)","0.77A","1opjB-1opkA:37.1","1opjA-1opkA:58.99"],["1OPJ_B_STIB4_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;VAL A 318;THR A 334;PHE A 336;GLY A 340;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-3.5A)","0.70A","1opjB-1opkA:37.1","1opjB-1opkA:58.99"],["1OPJ_B_STIB4_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;LYS A 290;VAL A 308;ILE A 332;MET A 337","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);None;P16 A   2 (-4.1A);None","0.53A","1opjB-1opkA:37.1","1opjB-1opkA:58.99"],["1T46_A_STIA3_1","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;VAL A 318;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.42A","1t46A-1opkA:30.7","1opjB-1opkA:58.99"],["1UWH_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"ALA A 288;GLU A 305;THR A 334;LEU A 373;HIS A 380","P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);None;None","0.54A","1uwhA-1opkA:26.6","1t46A-1opkA:24.75"],["1UWH_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"ALA A 288;LYS A 290;GLU A 305;THR A 334;LEU A 373;HIS A 380","P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);None;None","0.53A","1uwhB-1opkA:26.5","1uwhA-1opkA:21.19"],["1UWJ_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"VAL A 275;ALA A 288;GLU A 305;THR A 334;LEU A 373;HIS A 380","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);None;None","0.66A","1uwjA-1opkA:7.1","1uwhB-1opkA:21.19"],["1UWJ_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"VAL A 275;ALA A 288;GLU A 305;THR A 334;LEU A 373;HIS A 380","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);None;None","0.66A","1uwjB-1opkA:7.1","1uwjA-1opkA:21.19"],["1XKK_A_FMMA91_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"THR A 334;GLY A 340;LEU A 343;ASP A 344;ARG A 347;LEU A 389","P16 A   2 (-3.7A);P16 A   2 (-3.4A);None;None;None;P16 A   2 (-4.4A)","0.75A","1xkkA-1opkA:29.2","1uwjB-1opkA:21.19"],["1XKK_A_FMMA91_2","EPIDERMAL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;VAL A 275;LYS A 290;LEU A 320;MET A 337","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-4.5A);None;None","0.64A","1xkkA-1opkA:29.2","1xkkA-1opkA:24.91"],["2GQG_A_1N1A501_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",11,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;MET A 309;VAL A 318;ILE A 332;THR A 334;PHE A 336;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.82A","2gqgA-1opkA:37.1","1xkkA-1opkA:24.91"],["2GQG_A_1N1A501_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",11,"LEU A 267;ALA A 288;LYS A 290;MET A 309;VAL A 318;ILE A 332;THR A 334;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.80A","2gqgA-1opkA:37.1","2gqgA-1opkA:57.50"],["2GQG_B_1N1B502_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;VAL A 318;ILE A 332;THR A 334;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.57A","2gqgB-1opkA:37.9","2gqgA-1opkA:57.50"],["2GQG_B_1N1B502_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;MET A 309;VAL A 318;ILE A 332;THR A 334;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.62A","2gqgB-1opkA:37.9","2gqgB-1opkA:57.50"],["2GQG_B_1N1B502_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;VAL A 318;ILE A 332;THR A 334;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.59A","2gqgB-1opkA:37.9","2gqgB-1opkA:57.50"],["2GQG_B_1N1B502_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"VAL A 275;ALA A 288;LYS A 290;MET A 309;VAL A 318;ILE A 332;THR A 334;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.59A","2gqgB-1opkA:37.9","2gqgB-1opkA:57.50"],["2HYY_A_STIA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"TYR A 272;VAL A 275;ALA A 288;GLU A 305;MET A 309;THR A 334;PHE A 336;GLY A 340;LEU A 389","P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.87A","2hyyA-1opkA:34.9","2gqgB-1opkA:57.50"],["2HYY_A_STIA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;THR A 334;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.78A","2hyyA-1opkA:34.9","2hyyA-1opkA:99.27"],["2HYY_A_STIA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;LYS A 290;VAL A 308;VAL A 318;ILE A 332","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A)","0.59A","2hyyA-1opkA:34.9","2hyyA-1opkA:99.27"],["2HYY_A_STIA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LYS A 290;VAL A 308;VAL A 318;ILE A 332;ARG A 381","P16 A   2 (-4.5A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None","1.01A","2hyyA-1opkA:34.9","2hyyA-1opkA:99.27"],["2HYY_B_STIB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"TYR A 272;VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;THR A 334;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.88A","2hyyB-1opkA:34.7","2hyyA-1opkA:99.27"],["2HYY_B_STIB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;THR A 334;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.69A","2hyyB-1opkA:34.7","2hyyB-1opkA:99.27"],["2HYY_B_STIB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;LYS A 290;VAL A 308;VAL A 318;ILE A 332","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A)","0.54A","2hyyB-1opkA:34.7","2hyyB-1opkA:99.27"],["2HYY_B_STIB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LEU A 267;VAL A 308;ILE A 332;MET A 337","P16 A   2 ( 4.2A);None;P16 A   2 (-4.1A);None","0.44A","2hyyB-1opkA:34.7","2hyyB-1opkA:99.27"],["2HYY_C_STIC600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",11,"TYR A 272;VAL A 275;ALA A 288;GLU A 305;ILE A 312;VAL A 318;THR A 334;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);None;P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.84A","2hyyC-1opkA:35.2","2hyyB-1opkA:99.27"],["2HYY_C_STIC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;LYS A 290;VAL A 308;MET A 309;ILE A 332","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);None;P16 A   2 (-3.3A);P16 A   2 (-4.1A)","0.53A","2hyyC-1opkA:35.2","2hyyC-1opkA:99.27"],["2HYY_C_STIC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;VAL A 308;MET A 309;ILE A 332;MET A 337","P16 A   2 ( 4.2A);None;P16 A   2 (-3.3A);P16 A   2 (-4.1A);None","0.44A","2hyyC-1opkA:35.2","2hyyC-1opkA:99.27"],["2HYY_D_STID600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"TYR A 272;VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 332;THR A 334;PHE A 336;LEU A 389;ALA A 399","P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.87A","2hyyD-1opkA:34.8","2hyyC-1opkA:99.27"],["2HYY_D_STID600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;ILE A 332;THR A 334;PHE A 336;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.74A","2hyyD-1opkA:34.8","2hyyD-1opkA:99.27"],["2HYY_D_STID600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LEU A 267;LYS A 290;VAL A 318;MET A 337","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);None","0.58A","2hyyD-1opkA:34.8","2hyyD-1opkA:99.27"],["2ITO_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;MET A 309;THR A 334;GLY A 340","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-3.4A)","0.81A","2itoA-1opkA:30.3","2hyyD-1opkA:99.27"],["2ITO_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.83A","2itoA-1opkA:30.3","2itoA-1opkA:25.09"],["2ITY_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.94A","2ityA-1opkA:30.3","2itoA-1opkA:25.09"],["2ITZ_A_IREA2021_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;THR A 334;GLY A 340","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-3.4A)","0.82A","2itzA-1opkA:30.1","2ityA-1opkA:24.34"],["2ITZ_A_IREA2021_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.89A","2itzA-1opkA:30.1","2itzA-1opkA:24.15"],["2OIQ_A_STIA1001_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;ILE A 332;THR A 334;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.69A","2oiqA-1opkA:31.7","2itzA-1opkA:24.15"],["2PL0_A_STIA200_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"ALA A 288;GLU A 305;MET A 309;VAL A 318;ILE A 332;THR A 334;LEU A 389;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.74A","2pl0A-1opkA:30.2","2oiqA-1opkA:30.30"],["2PL0_A_STIA200_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"ALA A 288;LYS A 290;GLU A 305;MET A 309;VAL A 318;ILE A 332;THR A 334;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.5A)","0.72A","2pl0A-1opkA:30.2","2pl0A-1opkA:28.83"],["2PL0_A_STIA200_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 332;THR A 334;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.87A","2pl0A-1opkA:30.2","2pl0A-1opkA:28.83"],["2PL0_A_STIA200_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;ILE A 332;THR A 334;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.5A)","0.78A","2pl0A-1opkA:30.2","2pl0A-1opkA:28.83"],["2XP2_A_VGHA9000_1","TYROSINE-PROTEIN KINASE RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;VAL A 275;ALA A 288;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.58A","2xp2A-1opkA:30.8","2pl0A-1opkA:28.83"],["2Y6O_A_1N1A1892_1","EPHRIN TYPE-A RECEPTOR 4","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"ALA A 288;LYS A 290;GLU A 305;MET A 309;ILE A 332;THR A 334;GLY A 340;LEU A 389","P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.61A","2y6oA-1opkA:31.7","2xp2A-1opkA:25.98"],["2YFX_A_VGHA9000_1","TYROSINE-PROTEIN KINASE RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;ALA A 288;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.50A","2yfxA-1opkA:30.6","2y6oA-1opkA:26.16"],["2ZJ0_A_2FAA500_2","ADENOSYLHOMOCYSTEINASE","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"GLN A 319;THR A 334;HIS A 380;LEU A 403","None;P16 A   2 (-3.7A);None;None","1.39A","2zj0A-1opkA:undetectable","2yfxA-1opkA:25.98"],["2ZVA_A_1N1A513_1","TYROSINE-PROTEIN KINASE LYN","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",11,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;MET A 309;VAL A 318;ILE A 332;THR A 334;MET A 337;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.76A","2zvaA-1opkA:32.2","2zj0A-1opkA:21.13"],["2ZVA_A_1N1A513_1","TYROSINE-PROTEIN KINASE LYN","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",11,"LEU A 267;ALA A 288;LYS A 290;MET A 309;VAL A 318;ILE A 332;THR A 334;MET A 337;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.77A","2zvaA-1opkA:32.2","2zvaA-1opkA:28.48"],["3AOX_A_EMHA901_1","ALK TYROSINE KINASE RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;ALA A 288;VAL A 318;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 ( 4.7A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.74A","3aoxA-1opkA:30.4","2zvaA-1opkA:28.48"],["3C7Q_A_XINA1172_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;GLU A 277;ALA A 288;LYS A 290;VAL A 318;PHE A 336;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);None;P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.60A","3c7qA-1opkA:29.6","3aoxA-1opkA:27.15"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;TYR A 272;VAL A 275;LYS A 290;LYS A 304;ILE A 332;PHE A 336","P16 A   2 ( 4.2A);P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-4.5A);None;P16 A   2 (-4.1A);P16 A   2 ( 4.4A)","0.98A","3cs9A-1opkA:34.8","3c7qA-1opkA:26.37"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;TYR A 272;VAL A 275;LYS A 290;VAL A 318;ILE A 332;PHE A 336","P16 A   2 ( 4.2A);P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 ( 4.4A)","0.82A","3cs9A-1opkA:34.8","3cs9A-1opkA:57.29"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;VAL A 275;LYS A 290;VAL A 318;ILE A 332;PHE A 336;VAL A 398","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 ( 4.4A);None","0.64A","3cs9A-1opkA:34.8","3cs9A-1opkA:57.29"],["3CS9_A_NILA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"ALA A 288;GLU A 305;VAL A 308;MET A 309;LEU A 317;THR A 334;GLY A 340;HIS A 380;LEU A 389;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);None;P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 (-3.4A);None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.59A","3cs9A-1opkA:34.8","3cs9A-1opkA:57.29"],["3CS9_A_NILA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"GLU A 305;VAL A 308;MET A 309;ILE A 312;LEU A 317;THR A 334;GLY A 340;HIS A 380;LEU A 389;ALA A 399","P16 A   2 (-4.2A);None;P16 A   2 (-3.3A);None;None;P16 A   2 (-3.7A);P16 A   2 (-3.4A);None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.70A","3cs9A-1opkA:34.8","3cs9A-1opkA:57.29"],["3CS9_B_NILB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"ALA A 288;GLU A 305;VAL A 308;MET A 309;ILE A 312;LEU A 317;THR A 334;GLY A 340;HIS A 380;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);None;P16 A   2 (-3.3A);None;None;P16 A   2 (-3.7A);P16 A   2 (-3.4A);None;P16 A   2 (-3.5A)","0.66A","3cs9B-1opkA:34.3","3cs9A-1opkA:57.29"],["3CS9_B_NILB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;TYR A 272;VAL A 275;LYS A 290;VAL A 318;ILE A 332;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-4.4A)","0.73A","3cs9B-1opkA:34.3","3cs9B-1opkA:57.29"],["3CS9_B_NILB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;VAL A 275;LYS A 290;VAL A 318;ILE A 332;LEU A 389;VAL A 398","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-4.4A);None","0.53A","3cs9B-1opkA:34.3","3cs9B-1opkA:57.29"],["3CS9_B_NILB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;VAL A 275;VAL A 318;ILE A 332;PHE A 378;LEU A 389;VAL A 398","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None;P16 A   2 (-4.4A);None","0.68A","3cs9B-1opkA:34.3","3cs9B-1opkA:57.29"],["3CS9_C_NILC600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"ALA A 288;GLU A 305;VAL A 308;MET A 309;ILE A 312;LEU A 317;THR A 334;PHE A 336;HIS A 380;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);None;P16 A   2 (-3.3A);None;None;P16 A   2 (-3.7A);P16 A   2 ( 4.4A);None;P16 A   2 (-3.5A)","0.68A","3cs9C-1opkA:34.2","3cs9B-1opkA:57.29"],["3CS9_C_NILC600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"VAL A 308;MET A 309;ILE A 312;LEU A 317;THR A 334;PHE A 378","None;P16 A   2 (-3.3A);None;None;P16 A   2 (-3.7A);None","1.37A","3cs9C-1opkA:34.2","3cs9C-1opkA:57.29"],["3CS9_C_NILC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;VAL A 275;LYS A 290;VAL A 318;ILE A 332;MET A 337;VAL A 398","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None;None","0.64A","3cs9C-1opkA:34.2","3cs9C-1opkA:57.29"],["3CS9_C_NILC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"TYR A 272;VAL A 275;VAL A 318;ILE A 332;MET A 337","P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None","1.00A","3cs9C-1opkA:34.2","3cs9C-1opkA:57.29"],["3CS9_D_NILD600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"ALA A 288;GLU A 305;VAL A 308;MET A 309;LEU A 317;THR A 334;PHE A 336;GLY A 340;HIS A 380;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);None;P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);None;P16 A   2 (-3.5A)","0.59A","3cs9D-1opkA:33.0","3cs9C-1opkA:57.29"],["3CS9_D_NILD600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"GLU A 305;VAL A 308;MET A 309;ILE A 312;LEU A 317;THR A 334;GLY A 340;HIS A 380;ALA A 399","P16 A   2 (-4.2A);None;P16 A   2 (-3.3A);None;None;P16 A   2 (-3.7A);P16 A   2 (-3.4A);None;P16 A   2 (-3.5A)","0.72A","3cs9D-1opkA:33.0","3cs9D-1opkA:57.29"],["3CS9_D_NILD600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;TYR A 272;VAL A 275;LYS A 290;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-4.5A);P16 A   2 (-4.4A)","0.72A","3cs9D-1opkA:33.0","3cs9D-1opkA:57.29"],["3G0E_A_B49A9000_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;VAL A 275;ALA A 288;VAL A 318;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.39A","3g0eA-1opkA:29.3","3cs9D-1opkA:57.29"],["3G0F_A_B49A9001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;VAL A 275;ALA A 288;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.38A","3g0fA-1opkA:30.2","3g0eA-1opkA:26.33"],["3G0F_B_B49B9001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;VAL A 275;ALA A 288;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.33A","3g0fB-1opkA:30.5","3g0fA-1opkA:26.33"],["3G5D_A_1N1A1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;VAL A 318;ILE A 332;THR A 334;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.58A","3g5dA-1opkA:32.4","3g0fB-1opkA:26.33"],["3G5D_A_1N1A1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;MET A 309;VAL A 318;ILE A 332;THR A 334;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.64A","3g5dA-1opkA:32.4","3g5dA-1opkA:30.30"],["3G5D_B_1N1B1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",11,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;VAL A 318;THR A 334;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.78A","3g5dB-1opkA:32.5","3g5dA-1opkA:30.30"],["3GVU_A_STIA1001_1","TYROSINE-PROTEIN KINASE ABL2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;VAL A 318;THR A 334;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.61A","3gvuA-1opkA:35.4","3g5dB-1opkA:30.30"],["3GVU_A_STIA1001_1","TYROSINE-PROTEIN KINASE ABL2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"TYR A 272;VAL A 275;ALA A 288;GLU A 305;MET A 309;VAL A 318;THR A 334;LEU A 389","P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-4.4A)","0.85A","3gvuA-1opkA:35.4","3gvuA-1opkA:54.60"],["3GVU_A_STIA1001_1","TYROSINE-PROTEIN KINASE ABL2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;VAL A 318;THR A 334;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.72A","3gvuA-1opkA:35.4","3gvuA-1opkA:54.60"],["3GVU_A_STIA1001_2","TYROSINE-PROTEIN KINASE ABL2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LYS A 290;VAL A 308;ILE A 332;MET A 337","P16 A   2 (-4.5A);None;P16 A   2 (-4.1A);None","0.60A","3gvuA-1opkA:35.4","3gvuA-1opkA:54.60"],["3IK3_A_0LIA1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"ALA A 288;GLU A 305;MET A 309;ILE A 312;LEU A 317;HIS A 380;LEU A 389;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;None;None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.59A","3ik3A-1opkA:34.8","3gvuA-1opkA:54.60"],["3IK3_A_0LIA1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"GLU A 305;MET A 309;LEU A 317;VAL A 318;HIS A 380;LEU A 389","P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);None;P16 A   2 (-4.4A)","0.63A","3ik3A-1opkA:34.8","3ik3A-1opkA:57.78"],["3IK3_A_0LIA1_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LEU A 267;LYS A 290;VAL A 308;ILE A 332","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);None;P16 A   2 (-4.1A)","0.53A","3ik3A-1opkA:34.8","3ik3A-1opkA:57.78"],["3IK3_A_0LIA1_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LEU A 267;VAL A 308;ILE A 332;MET A 337","P16 A   2 ( 4.2A);None;P16 A   2 (-4.1A);None","0.34A","3ik3A-1opkA:34.8","3ik3A-1opkA:57.78"],["3IK3_B_0LIB2_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"ALA A 288;GLU A 305;MET A 309;ILE A 312;LEU A 317;HIS A 380;LEU A 389;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;None;None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.57A","3ik3B-1opkA:34.6","3ik3A-1opkA:57.78"],["3IK3_B_0LIB2_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"GLU A 305;MET A 309;LEU A 317;VAL A 318;HIS A 380;LEU A 389","P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);None;P16 A   2 (-4.4A)","0.67A","3ik3B-1opkA:34.6","3ik3B-1opkA:57.78"],["3IK3_B_0LIB2_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LEU A 267;LYS A 290;VAL A 308;ILE A 332","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);None;P16 A   2 (-4.1A)","0.50A","3ik3B-1opkA:34.6","3ik3B-1opkA:57.78"],["3IK3_B_0LIB2_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LEU A 267;VAL A 308;ILE A 332;MET A 337","P16 A   2 ( 4.2A);None;P16 A   2 (-4.1A);None","0.35A","3ik3B-1opkA:34.6","3ik3B-1opkA:57.78"],["3K54_A_1N1A1_1","TYROSINE-PROTEIN KINASE BTK","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;MET A 309;VAL A 318;ILE A 332;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.79A","3k54A-1opkA:30.3","3ik3B-1opkA:57.78"],["3K5V_A_STIA2_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"TYR A 272;VAL A 275;ALA A 288;GLU A 305;MET A 309;THR A 334;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.81A","3k5vA-1opkA:37.0","3k54A-1opkA:29.12"],["3K5V_A_STIA2_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;THR A 334;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.71A","3k5vA-1opkA:37.0","3k5vA-1opkA:58.99"],["3K5V_A_STIA2_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;LYS A 290;VAL A 308;VAL A 318;ILE A 332","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A)","0.52A","3k5vA-1opkA:37.0","3k5vA-1opkA:58.99"],["3K5V_A_STIA2_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LEU A 267;VAL A 308;ILE A 332;MET A 337","P16 A   2 ( 4.2A);None;P16 A   2 (-4.1A);None","0.45A","3k5vA-1opkA:37.0","3k5vA-1opkA:58.99"],["3K5V_B_STIB2_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"TYR A 272;VAL A 275;ALA A 288;GLU A 305;MET A 309;THR A 334;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.83A","3k5vB-1opkA:37.2","3k5vA-1opkA:58.99"],["3K5V_B_STIB2_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;THR A 334;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.68A","3k5vB-1opkA:37.2","3k5vB-1opkA:58.99"],["3K5V_B_STIB2_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;LYS A 290;VAL A 308;VAL A 318;ILE A 332","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A)","0.50A","3k5vB-1opkA:37.2","3k5vB-1opkA:58.99"],["3K5V_B_STIB2_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;VAL A 308;VAL A 318;ILE A 332;MET A 337","P16 A   2 ( 4.2A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None","0.47A","3k5vB-1opkA:37.2","3k5vB-1opkA:58.99"],["3LFA_A_1N1A361_1","MITOGEN-ACTIVATED PROTEIN KINASE 14","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"ALA A 288;LYS A 290;GLU A 305;THR A 334;MET A 337","P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);None","0.45A","3lfaA-1opkA:19.7","3k5vB-1opkA:58.99"],["3MIY_A_B49A1_1","TYROSINE-PROTEIN KINASE ITK\/TSK","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"ALA A 288;VAL A 318;PHE A 336;MET A 337;GLY A 340;LEU A 389","P16 A   2 (-3.4A);P16 A   2 ( 4.7A);P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.74A","3miyA-1opkA:30.8","3lfaA-1opkA:22.77"],["3MIY_B_B49B2_1","TYROSINE-PROTEIN KINASE ITK\/TSK","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"ALA A 288;PHE A 336;MET A 337;GLY A 340;LEU A 389","P16 A   2 (-3.4A);P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.59A","3miyB-1opkA:31.0","3miyA-1opkA:26.01"],["3MS9_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;TYR A 272;VAL A 275;ALA A 288;GLU A 305;MET A 309;THR A 334;PHE A 336;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-4.4A)","0.79A","3ms9A-1opkA:34.3","3miyB-1opkA:26.01"],["3MS9_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;THR A 334;PHE A 336;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.76A","3ms9A-1opkA:34.3","3ms9A-1opkA:58.99"],["3MS9_A_STIA1_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LYS A 290;VAL A 308;VAL A 318;ILE A 332;MET A 337","P16 A   2 (-4.5A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None","0.57A","3ms9A-1opkA:34.3","3ms9A-1opkA:58.99"],["3MS9_A_STIA1_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LYS A 290;VAL A 318;ILE A 332;MET A 337;ARG A 381","P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None;None","0.95A","3ms9A-1opkA:34.3","3ms9A-1opkA:58.99"],["3MS9_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",11,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;THR A 334;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.74A","3ms9B-1opkA:34.5","3ms9A-1opkA:58.99"],["3MS9_B_STIB1_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LYS A 290;VAL A 308;VAL A 318;ILE A 332","P16 A   2 (-4.5A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A)","0.54A","3ms9B-1opkA:34.5","3ms9B-1opkA:58.99"],["3MS9_B_STIB1_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"TYR A 272;VAL A 308;VAL A 318;ILE A 332;MET A 337","P16 A   2 (-3.6A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None","0.70A","3ms9B-1opkA:34.5","3ms9B-1opkA:58.99"],["3MSS_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;TYR A 272;VAL A 275;ALA A 288;GLU A 305;MET A 309;THR A 334;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-4.4A)","0.76A","3mssA-1opkA:34.5","3ms9B-1opkA:58.99"],["3MSS_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;THR A 334;PHE A 336;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.74A","3mssA-1opkA:34.5","3mssA-1opkA:58.99"],["3MSS_A_STIA1_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LYS A 290;VAL A 308;VAL A 318;ILE A 332","P16 A   2 (-4.5A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A)","0.47A","3mssA-1opkA:34.5","3mssA-1opkA:58.99"],["3MSS_A_STIA1_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LYS A 290;VAL A 318;ILE A 332;ARG A 381","P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None","0.97A","3mssA-1opkA:34.5","3mssA-1opkA:58.99"],["3MSS_A_STIA1_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"VAL A 308;VAL A 318;ILE A 332;MET A 337","None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None","0.46A","3mssA-1opkA:34.5","3mssA-1opkA:58.99"],["3MSS_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"GLU A 305;MET A 309;ILE A 312;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.64A","3mssB-1opkA:34.6","3mssA-1opkA:58.99"],["3MSS_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"GLU A 305;MET A 309;ILE A 312;THR A 334;GLY A 340;LEU A 389","P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.60A","3mssB-1opkA:34.6","3mssB-1opkA:58.99"],["3MSS_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.68A","3mssB-1opkA:34.6","3mssB-1opkA:58.99"],["3MSS_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;THR A 334;PHE A 336;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.63A","3mssB-1opkA:34.6","3mssB-1opkA:58.99"],["3MSS_B_STIB1_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"TYR A 272;LYS A 290;VAL A 308;VAL A 318;ILE A 332","P16 A   2 (-3.6A);P16 A   2 (-4.5A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A)","0.90A","3mssB-1opkA:34.6","3mssB-1opkA:58.99"],["3MSS_B_STIB1_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"TYR A 272;VAL A 308;VAL A 318;ILE A 332;MET A 337","P16 A   2 (-3.6A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None","0.73A","3mssB-1opkA:34.6","3mssB-1opkA:58.99"],["3MSS_C_STIC1_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;TYR A 272;VAL A 275;ALA A 288;GLU A 305;MET A 309;THR A 334;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-4.4A)","0.78A","3mssC-1opkA:34.5","3mssB-1opkA:58.99"],["3MSS_C_STIC1_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;THR A 334;PHE A 336;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.75A","3mssC-1opkA:34.5","3mssC-1opkA:58.99"],["3MSS_C_STIC1_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LYS A 290;VAL A 308;VAL A 318;ILE A 332","P16 A   2 (-4.5A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A)","0.48A","3mssC-1opkA:34.5","3mssC-1opkA:58.99"],["3MSS_C_STIC1_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LYS A 290;VAL A 318;ILE A 332;ARG A 381","P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None","1.00A","3mssC-1opkA:34.5","3mssC-1opkA:58.99"],["3MSS_C_STIC1_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"VAL A 308;VAL A 318;ILE A 332;MET A 337","None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None","0.48A","3mssC-1opkA:34.5","3mssC-1opkA:58.99"],["3MSS_D_STID1_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;ALA A 288;GLU A 305;MET A 309;ILE A 312;THR A 334;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.79A","3mssD-1opkA:34.6","3mssC-1opkA:58.99"],["3MSS_D_STID1_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;TYR A 272;ALA A 288;GLU A 305;MET A 309;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.6A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.84A","3mssD-1opkA:34.6","3mssD-1opkA:58.99"],["3MSS_D_STID1_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"VAL A 275;LYS A 290;VAL A 308;VAL A 318;ILE A 332","P16 A   2 (-4.5A);P16 A   2 (-4.5A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A)","0.52A","3mssD-1opkA:34.6","3mssD-1opkA:58.99"],["3MSS_D_STID1_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"VAL A 275;VAL A 308;VAL A 318;ILE A 332;MET A 337","P16 A   2 (-4.5A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None","0.50A","3mssD-1opkA:34.6","3mssD-1opkA:58.99"],["3OCT_A_1N1A663_1","TYROSINE-PROTEIN KINASE BTK","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;MET A 309;VAL A 318;THR A 334;GLY A 340;GLU A 348;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);None;P16 A   2 (-4.4A)","1.12A","3octA-1opkA:32.5","3mssD-1opkA:58.99"],["3OEZ_A_STIA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"ALA A 288;GLU A 305;MET A 309;ILE A 312;THR A 334;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.57A","3oezA-1opkA:31.3","3octA-1opkA:28.69"],["3OEZ_A_STIA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"ALA A 288;GLU A 305;MET A 309;ILE A 312;VAL A 318;THR A 334;GLY A 340;LEU A 389","P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.49A","3oezA-1opkA:31.3","3oezA-1opkA:30.51"],["3OEZ_A_STIA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"VAL A 275;ALA A 288;GLU A 305;MET A 309;THR A 334;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.69A","3oezA-1opkA:31.3","3oezA-1opkA:30.51"],["3OEZ_A_STIA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"VAL A 275;ALA A 288;GLU A 305;MET A 309;VAL A 318;THR A 334;GLY A 340;LEU A 389","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.63A","3oezA-1opkA:31.3","3oezA-1opkA:30.51"],["3OEZ_B_STIB601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"ALA A 288;LYS A 290;GLU A 305;VAL A 308;MET A 309;ILE A 332;THR A 334;LEU A 389;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);None;P16 A   2 (-3.3A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.66A","3oezB-1opkA:31.4","3oezA-1opkA:30.51"],["3OEZ_B_STIB601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"VAL A 275;ALA A 288;LYS A 290;VAL A 308;MET A 309;ILE A 332;THR A 334;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);None;P16 A   2 (-3.3A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.67A","3oezB-1opkA:31.4","3oezB-1opkA:30.51"],["3OND_A_ADNA506_2","ADENOSYLHOMOCYSTEINASE","4crm","TRANSLATION INITIATION FACTOR RLI1","Saccharomyces cerevisiae",3,"GLN P 127;THR P 118;LEU P 131","None;ATP P1609 (-3.6A);None","0.75A","3ondA-4crmP:undetectable","3oezB-1opkA:30.51"],["3OND_B_ADNB507_2","ADENOSYLHOMOCYSTEINASE","4crm","TRANSLATION INITIATION FACTOR RLI1","Saccharomyces cerevisiae",3,"GLN P 127;THR P 118;LEU P 131","None;ATP P1609 (-3.6A);None","0.76A","3ondB-4crmP:undetectable","3ondA-4crmP:21.74"],["3OXZ_A_0LIA1_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"ALA A 288;GLU A 305;MET A 309;ILE A 312;LEU A 317;THR A 334;GLY A 340;HIS A 380;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;None;P16 A   2 (-3.7A);P16 A   2 (-3.4A);None;P16 A   2 (-3.5A)","0.52A","3oxzA-1opkA:34.6","3ondB-4crmP:21.74"],["3OXZ_A_0LIA1_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"ALA A 288;GLU A 305;MET A 309;ILE A 312;LEU A 317;VAL A 318;THR A 334;GLY A 340;HIS A 380","P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;None;P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);None","0.50A","3oxzA-1opkA:34.6","3oxzA-1opkA:57.64"],["3OXZ_A_0LIA1_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;LYS A 290;VAL A 308;ILE A 332;MET A 337;LEU A 389;VAL A 398","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);None;P16 A   2 (-4.1A);None;P16 A   2 (-4.4A);None","0.50A","3oxzA-1opkA:34.6","3oxzA-1opkA:57.64"],["3PYY_A_STIA3_1","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;THR A 334;PHE A 336","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 ( 4.4A)","0.53A","3pyyA-1opkA:34.3","3oxzA-1opkA:57.64"],["3PYY_A_STIA3_1","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;THR A 334;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.67A","3pyyA-1opkA:34.3","3pyyA-1opkA:59.18"],["3PYY_A_STIA3_2","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LYS A 290;VAL A 318;ILE A 332;ARG A 381","P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);None","1.02A","3pyyA-1opkA:34.3","3pyyA-1opkA:59.18"],["3PYY_A_STIA3_2","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"TYR A 272;LYS A 290;VAL A 308;VAL A 318;ILE A 332","P16 A   2 (-3.6A);P16 A   2 (-4.5A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A)","0.92A","3pyyA-1opkA:34.3","3pyyA-1opkA:59.18"],["3PYY_B_STIB4_1","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;TYR A 272;VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;VAL A 318;THR A 334;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-4.4A)","0.77A","3pyyB-1opkA:34.6","3pyyA-1opkA:59.18"],["3PYY_B_STIB4_1","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;VAL A 318;THR A 334;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.59A","3pyyB-1opkA:34.6","3pyyB-1opkA:59.18"],["3PYY_B_STIB4_2","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LYS A 290;VAL A 308;ILE A 332;MET A 337;ARG A 381","P16 A   2 (-4.5A);None;P16 A   2 (-4.1A);None;None","0.93A","3pyyB-1opkA:34.6","3pyyB-1opkA:59.18"],["3QLG_A_1N1A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",11,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;VAL A 318;THR A 334;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.81A","3qlgA-1opkA:31.7","3pyyB-1opkA:59.18"],["3QLG_B_1N1B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;VAL A 318;THR A 334;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.76A","3qlgB-1opkA:32.0","3qlgA-1opkA:30.51"],["3SXR_A_1N1A1_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;VAL A 275;ALA A 288;MET A 309;VAL A 318;ILE A 332;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.62A","3sxrA-1opkA:33.1","3qlgB-1opkA:30.51"],["3SXR_B_1N1B2_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;VAL A 275;ALA A 288;MET A 309;VAL A 318;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.58A","3sxrB-1opkA:32.9","3sxrA-1opkA:25.71"],["3UE4_A_DB8A601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;ALA A 288;GLU A 305;THR A 334;PHE A 336;MET A 337;GLY A 340;LEU A 389;PHE A 401","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A);None","0.95A","3ue4A-1opkA:37.4","3sxrB-1opkA:25.71"],["3UE4_A_DB8A601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;ILE A 332;THR A 334;PHE A 336;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.73A","3ue4A-1opkA:37.4","3ue4A-1opkA:57.72"],["3UE4_A_DB8A601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;ALA A 288;LYS A 290;VAL A 318;ILE A 332;THR A 334;PHE A 336;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.65A","3ue4A-1opkA:37.4","3ue4A-1opkA:57.72"],["3UE4_A_DB8A601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;ALA A 288;VAL A 318;THR A 334;PHE A 336;MET A 337;GLY A 340;LEU A 389;PHE A 401","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A);None","0.78A","3ue4A-1opkA:37.4","3ue4A-1opkA:57.72"],["3UE4_B_DB8B601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",11,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;VAL A 318;ILE A 332;THR A 334;PHE A 336;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.67A","3ue4B-1opkA:37.8","3ue4A-1opkA:57.72"],["3UE4_B_DB8B601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",11,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;VAL A 318;THR A 334;PHE A 336;GLY A 340;LEU A 389;PHE A 401","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);None","0.89A","3ue4B-1opkA:37.8","3ue4B-1opkA:57.72"],["3UG2_A_IREA1_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;MET A 337;GLY A 340;ASP A 344;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);None;P16 A   2 (-3.4A);None;P16 A   2 (-4.4A)","0.81A","3ug2A-1opkA:31.8","3ue4B-1opkA:57.72"],["3WZD_A_LEVA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;GLY A 268;VAL A 275;ALA A 288;GLY A 340","P16 A   2 ( 4.2A);P16 A   2 ( 4.3A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-3.4A)","0.40A","3wzdA-1opkA:30.6","3ug2A-1opkA:25.85"],["3WZD_A_LEVA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;GLY A 340","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.4A)","0.37A","3wzdA-1opkA:30.6","3wzdA-1opkA:25.10"],["3WZE_A_BAXA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;PHE A 336;GLY A 340;LEU A 373;HIS A 380","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);None;None","0.44A","3wzeA-1opkA:30.3","3wzdA-1opkA:25.10"],["3WZE_A_BAXA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;PHE A 336;GLY A 340;HIS A 380","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);None","0.54A","3wzeA-1opkA:30.3","3wzeA-1opkA:25.10"],["3ZOS_A_0LIA1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;THR A 334;LEU A 373;HIS A 380;ARG A 381;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);None;None;None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.90A","3zosA-1opkA:29.5","3wzeA-1opkA:25.10"],["3ZOS_B_0LIB1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"ALA A 288;LYS A 290;GLU A 305;THR A 334;LEU A 373;HIS A 380;ARG A 381;LEU A 389;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);None;None;None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.92A","3zosB-1opkA:29.4","3zosA-1opkA:26.49"],["4AG8_A_AXIA2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;VAL A 318;PHE A 336;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 ( 4.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.44A","4ag8A-1opkA:30.7","3zosB-1opkA:26.49"],["4AGC_A_AXIA2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.47A","4agcA-1opkA:30.2","4ag8A-1opkA:26.37"],["4AGD_A_B49A2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;ALA A 288;VAL A 318;PHE A 336;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 ( 4.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.35A","4agdA-1opkA:29.8","4agcA-1opkA:28.12"],["4ANQ_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;VAL A 275;ALA A 288;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.56A","4anqA-1opkA:30.6","4agdA-1opkA:28.12"],["4ANS_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;VAL A 275;ALA A 288;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.57A","4ansA-1opkA:30.5","4anqA-1opkA:27.54"],["4ASD_A_BAXA1500_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;PHE A 336;GLY A 340;LEU A 373;HIS A 380","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);None;None","0.62A","4asdA-1opkA:30.0","4ansA-1opkA:27.54"],["4BKJ_A_STIA1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"VAL A 275;ALA A 288;GLU A 305;MET A 309;THR A 334;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.93A","4bkjA-1opkA:28.8","4asdA-1opkA:28.12"],["4BKJ_B_STIB1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"VAL A 275;ALA A 288;GLU A 305;MET A 309;THR A 334;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.80A","4bkjB-1opkA:28.8","4bkjA-1opkA:26.49"],["4C8B_A_0LIA1000_1","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"ALA A 288;LYS A 290;GLU A 305;ILE A 332;THR A 334;HIS A 380;LEU A 389;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.50A","4c8bA-1opkA:25.4","4bkjB-1opkA:26.49"],["4C8B_B_0LIB1000_1","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"ALA A 288;LYS A 290;GLU A 305;THR A 334;HIS A 380;LEU A 389;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.47A","4c8bB-1opkA:25.6","4c8bA-1opkA:20.68"],["4CSV_A_STIA1265_1","SRC-ABL TYROSINE KINASE ANCESTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"VAL A 275;ALA A 288;GLU A 305;MET A 309;THR A 334;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.65A","4csvA-1opkA:32.5","4c8bB-1opkA:20.68"],["4CSV_A_STIA1265_1","SRC-ABL TYROSINE KINASE ANCESTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"VAL A 275;ALA A 288;GLU A 305;MET A 309;VAL A 318;THR A 334;LEU A 389","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-4.4A)","0.63A","4csvA-1opkA:32.5","4csvA-1opkA:47.67"],["4CSV_A_STIA1265_2","SRC-ABL TYROSINE KINASE ANCESTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LYS A 290;ILE A 332;MET A 337;PHE A 378","P16 A   2 (-4.5A);P16 A   2 (-4.1A);None;None","0.63A","4csvA-1opkA:32.2","4csvA-1opkA:47.67"],["4HJO_A_AQ4A1001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;THR A 334;MET A 337;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.7A);None;P16 A   2 (-4.4A)","0.67A","4hjoA-1opkA:29.7","4csvA-1opkA:47.67"],["4HJO_A_AQ4A1001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;VAL A 275;ALA A 288;THR A 334;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-3.7A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.63A","4hjoA-1opkA:29.7","4hjoA-1opkA:25.00"],["4MKC_A_4MKA1503_1","ALK TYROSINE KINASE RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;GLY A 273;VAL A 275;ALA A 288;LYS A 290;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);None;P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.87A","4mkcA-1opkA:30.9","4hjoA-1opkA:25.00"],["4MXO_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;VAL A 318;ILE A 332;THR A 334","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A)","0.72A","4mxoA-1opkA:32.1","4mkcA-1opkA:28.43"],["4MXO_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;MET A 309;VAL A 318;ILE A 332;THR A 334;GLY A 340","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A)","0.86A","4mxoA-1opkA:32.1","4mxoA-1opkA:30.30"],["4MXO_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;VAL A 318;ILE A 332;THR A 334","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A)","0.70A","4mxoB-1opkA:32.1","4mxoA-1opkA:30.30"],["4MXO_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;VAL A 318;ILE A 332;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.73A","4mxoB-1opkA:32.1","4mxoB-1opkA:30.30"],["4MXX_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"ALA A 288;LYS A 290;GLU A 305;MET A 309;VAL A 318;THR A 334;GLY A 340;LEU A 389","P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.88A","4mxxA-1opkA:32.1","4mxoB-1opkA:30.30"],["4MXX_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"ALA A 288;LYS A 290;GLU A 305;VAL A 318;ILE A 332;THR A 334;GLY A 340;LEU A 389","P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.78A","4mxxA-1opkA:32.1","4mxxA-1opkA:30.10"],["4MXX_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;ILE A 332;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.93A","4mxxA-1opkA:32.1","4mxxA-1opkA:30.10"],["4MXX_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;MET A 309;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","1.04A","4mxxA-1opkA:32.1","4mxxA-1opkA:30.10"],["4MXX_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;VAL A 318;THR A 334;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.78A","4mxxB-1opkA:31.6","4mxxA-1opkA:30.10"],["4MXY_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;VAL A 318;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.96A","4mxyB-1opkA:32.1","4mxxB-1opkA:30.10"],["4MXZ_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;VAL A 318;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.96A","4mxzB-1opkA:32.1","4mxyB-1opkA:29.90"],["4OTW_A_DB8A1101_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;VAL A 275;LYS A 290;VAL A 318;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.90A","4otwA-1opkA:28.5","4mxzB-1opkA:29.90"],["4OTW_A_DB8A1101_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;VAL A 275;LYS A 290;VAL A 318;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.74A","4otwA-1opkA:28.5","4otwA-1opkA:24.20"],["4QMN_A_DB8A401_1","SERINE\/THREONINE-PROTEIN KINASE 24","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"ALA A 288;LYS A 290;GLU A 305;ILE A 332;LEU A 389;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-4.1A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.80A","4qmnA-1opkA:26.0","4otwA-1opkA:24.20"],["4QRC_A_0LIA802_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"ALA A 288;GLU A 305;MET A 309;LEU A 373;ARG A 381;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;None;P16 A   2 (-3.5A)","0.83A","4qrcA-1opkA:30.7","4qmnA-1opkA:22.38"],["4QRC_A_0LIA802_2","FIBROBLAST GROWTH FACTOR RECEPTOR 4","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;VAL A 275;LYS A 290;HIS A 380;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-4.5A);None;P16 A   2 (-4.4A)","0.48A","4qrcA-1opkA:30.7","4qrcA-1opkA:29.08"],["4R7I_A_STIA1001_1","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;THR A 334;LEU A 389","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-4.4A)","0.45A","4r7iA-1opkA:30.3","4qrcA-1opkA:29.08"],["4RJD_B_TFPB204_1","CALMODULIN;CALMODULIN","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LEU A 395;GLY A 391;GLU A 392;ALA A 288","None;GOL A   3 (-4.9A);GOL A   3 (-4.5A);P16 A   2 (-3.4A)","0.88A","4rjdA-1opkA:0.0;4rjdB-1opkA:0.0","4r7iA-1opkA:26.94"],["4TWP_A_AXIA601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;PHE A 336;MET A 337;GLY A 340;ASN A 387;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A);None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.50A","4twpA-1opkA:37.7","4rjdA-1opkA:12.43;4rjdB-1opkA:12.43"],["4TWP_A_AXIA601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"TYR A 272;VAL A 275;ALA A 288;LYS A 290;PHE A 336;MET A 337;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.91A","4twpA-1opkA:37.7","4twpA-1opkA:98.89"],["4TWP_B_AXIB601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;TYR A 272;VAL A 275;ALA A 288;LYS A 290;PHE A 336;MET A 337;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.80A","4twpB-1opkA:38.4","4twpA-1opkA:98.89"],["4TWP_B_AXIB601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;PHE A 336;MET A 337;GLY A 340;ASN A 387;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A);None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.51A","4twpB-1opkA:38.4","4twpB-1opkA:98.89"],["4TYJ_A_0LIA801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"ALA A 288;GLU A 305;MET A 309;ILE A 312;HIS A 380;LEU A 389;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.64A","4tyjA-1opkA:30.8","4twpB-1opkA:98.89"],["4U0I_A_0LIA1001_2","MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"ALA A 288;LYS A 290;THR A 334;GLY A 340;HIS A 380;LEU A 389","P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);None;P16 A   2 (-4.4A)","0.47A","4u0iA-1opkA:30.5","4tyjA-1opkA:28.43"],["4U5J_A_RXTA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;VAL A 275;ALA A 288;MET A 337;GLY A 340;ASN A 387;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);None;P16 A   2 (-3.4A);None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.64A","4u5jA-1opkA:33.6","4u0iA-1opkA:24.95"],["4U5J_B_RXTB601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;VAL A 275;ALA A 288;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.48A","4u5jB-1opkA:32.9","4u5jA-1opkA:30.30"],["4UXQ_A_0LIA1752_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"ALA A 288;GLU A 305;ILE A 312;LEU A 373;HIS A 380;LEU A 389","P16 A   2 (-3.4A);P16 A   2 (-4.2A);None;None;None;P16 A   2 (-4.4A)","0.85A","4uxqA-1opkA:30.4","4u5jB-1opkA:30.30"],["4UXQ_A_0LIA1752_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;ALA A 288;GLU A 305;LEU A 373;HIS A 380;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);None;None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.66A","4uxqA-1opkA:30.4","4uxqA-1opkA:28.18"],["4V01_A_0LIA1776_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"ALA A 288;GLU A 305;MET A 309;ILE A 312;LEU A 373;HIS A 380;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;None;None;P16 A   2 (-3.5A)","0.85A","4v01A-1opkA:29.9","4uxqA-1opkA:28.18"],["4V01_B_0LIB1770_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"ALA A 288;GLU A 305;MET A 309;LEU A 373;HIS A 380;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;None;P16 A   2 (-3.5A)","0.59A","4v01B-1opkA:30.1","4v01A-1opkA:27.68"],["4V04_A_0LIA1772_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"VAL A 275;ALA A 288;GLU A 305;HIS A 380;ALA A 399;GLY A 402","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);None;P16 A   2 (-3.5A);None","1.08A","4v04A-1opkA:29.6","4v01B-1opkA:27.68"],["4V04_A_0LIA1772_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"VAL A 275;ALA A 288;GLU A 305;LEU A 373;HIS A 380;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);None;None;P16 A   2 (-3.5A)","0.63A","4v04A-1opkA:29.6","4v04A-1opkA:27.68"],["4V04_B_0LIB1771_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"ALA A 288;GLU A 305;LEU A 373;HIS A 380;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-4.2A);None;None;P16 A   2 (-3.5A)","0.63A","4v04B-1opkA:29.8","4v04A-1opkA:27.68"],["4WA9_A_AXIA9000_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"ALA A 288;THR A 334;MET A 337;GLY A 340;ASN A 387;LEU A 389;ALA A 399","P16 A   2 (-3.4A);P16 A   2 (-3.7A);None;P16 A   2 (-3.4A);None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.52A","4wa9A-1opkA:33.1","4v04B-1opkA:27.68"],["4WA9_A_AXIA9000_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;ALA A 288;LYS A 290;THR A 334;MET A 337;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.7A);None;P16 A   2 (-4.4A)","1.01A","4wa9A-1opkA:33.1","4wa9A-1opkA:57.72"],["4WA9_A_AXIA9000_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;ALA A 288;THR A 334;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-3.7A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.84A","4wa9A-1opkA:33.1","4wa9A-1opkA:57.72"],["4WA9_A_AXIA9000_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"TYR A 272;ALA A 288;THR A 334;MET A 337;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-3.6A);P16 A   2 (-3.4A);P16 A   2 (-3.7A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.85A","4wa9A-1opkA:33.1","4wa9A-1opkA:57.72"],["4WA9_B_AXIB9000_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"TYR A 272;VAL A 275;ALA A 288;THR A 334;MET A 337;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-3.7A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.79A","4wa9B-1opkA:37.8","4wa9A-1opkA:57.72"],["4WA9_B_AXIB9000_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"VAL A 275;ALA A 288;LYS A 290;THR A 334;PHE A 336;MET A 337;GLY A 340;ASN A 387;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A);None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.54A","4wa9B-1opkA:37.8","4wa9B-1opkA:57.72"],["4WBO_C_ANWC601_0","RHODOPSIN KINASE","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LEU A 267;ALA A 288;MET A 337;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);None;P16 A   2 (-4.4A)","0.50A","4wboC-1opkA:22.0","4wa9B-1opkA:57.72"],["4WKQ_A_IREA1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;ALA A 288;GLU A 305;THR A 334;GLY A 340;ASP A 344;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);None;P16 A   2 (-4.4A)","0.88A","4wkqA-1opkA:32.1","4wboC-1opkA:26.45"],["4WKQ_A_IREA1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;MET A 309;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.76A","4wkqA-1opkA:32.1","4wkqA-1opkA:24.91"],["4XEY_A_1N1A601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",12,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;MET A 309;VAL A 318;ILE A 332;THR A 334;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.63A","4xeyA-1opkA:37.1","4wkqA-1opkA:24.91"],["4XEY_B_1N1B601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;VAL A 318;ILE A 332;THR A 334;PHE A 336;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-4.4A)","0.60A","4xeyB-1opkA:36.3","4xeyA-1opkA:80.12"],["4XEY_B_1N1B601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;VAL A 275;ALA A 288;VAL A 318;ILE A 332;THR A 334;PHE A 336;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.62A","4xeyB-1opkA:36.3","4xeyB-1opkA:80.12"],["4XEY_B_1N1B601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"VAL A 275;ALA A 288;LYS A 290;MET A 309;VAL A 318;ILE A 332;THR A 334;PHE A 336;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.52A","4xeyB-1opkA:36.3","4xeyB-1opkA:80.12"],["4XEY_B_1N1B601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"VAL A 275;ALA A 288;MET A 309;VAL A 318;ILE A 332;THR A 334;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.47A","4xeyB-1opkA:36.3","4xeyB-1opkA:80.12"],["4XLI_A_1N1A601_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",11,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;MET A 309;VAL A 318;THR A 334;MET A 337;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.72A","4xliA-1opkA:36.5","4xeyB-1opkA:80.12"],["4XLI_B_1N1B600_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",11,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;MET A 309;VAL A 318;ILE A 332;THR A 334;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.68A","4xliB-1opkA:36.7","4xliA-1opkA:92.16"],["4ZAU_A_YY3A1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;VAL A 275;ALA A 288;MET A 337;GLY A 340","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);None;P16 A   2 (-3.4A)","0.59A","4zauA-1opkA:31.9","4xliB-1opkA:92.16"],["5AAA_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;VAL A 275;ALA A 288;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.56A","5aaaA-1opkA:31.0","4zauA-1opkA:24.91"],["5AAB_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.65A","5aabA-1opkA:31.0","5aaaA-1opkA:26.17"],["5AAC_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.74A","5aacA-1opkA:30.9","5aabA-1opkA:26.17"],["5AJQ_A_DB8A800_1","SERINE\/THREONINE-PROTEIN KINASE 10","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;ALA A 288;LYS A 290;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","1.04A","5ajqA-1opkA:22.7","5aacA-1opkA:25.98"],["5AJQ_A_DB8A800_1","SERINE\/THREONINE-PROTEIN KINASE 10","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;GLY A 268;ALA A 288;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 ( 4.3A);P16 A   2 (-3.4A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.98A","5ajqA-1opkA:22.7","5ajqA-1opkA:19.54"],["5AJQ_B_DB8B800_1","SERINE\/THREONINE-PROTEIN KINASE 10","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"ALA A 288;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-3.4A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.68A","5ajqB-1opkA:23.0","5ajqA-1opkA:19.54"],["5BVW_A_1N1A1009_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;THR A 334;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.59A","5bvwA-1opkA:29.8","5ajqB-1opkA:19.54"],["5H2U_A_1N1A501_1","PROTEIN-TYROSINE KINASE 6","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;VAL A 275;ALA A 288;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.74A","5h2uA-1opkA:29.5","5bvwA-1opkA:26.68"],["5H2U_B_1N1B501_1","PROTEIN-TYROSINE KINASE 6","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;VAL A 275;ALA A 288;ILE A 332;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.78A","5h2uB-1opkA:29.5","5h2uA-1opkA:25.41"],["5H2U_C_1N1C501_1","PROTEIN-TYROSINE KINASE 6","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;ALA A 288;ILE A 332;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.75A","5h2uC-1opkA:29.3","5h2uB-1opkA:25.41"],["5HES_A_032A401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"GLY A 268;VAL A 275;ALA A 288;ILE A 332;THR A 334","P16 A   2 ( 4.3A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.1A);P16 A   2 (-3.7A)","0.69A","5hesA-1opkA:10.6","5h2uC-1opkA:25.41"],["5HES_B_032B401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"GLY A 268;ALA A 288;LYS A 290;ILE A 332;THR A 334;ASP A 344","P16 A   2 ( 4.3A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);None","1.00A","5hesB-1opkA:27.3","5hesA-1opkA:20.81"],["5HES_B_032B401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"GLY A 268;VAL A 275;ALA A 288;LYS A 290;ILE A 332;THR A 334","P16 A   2 ( 4.3A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.1A);P16 A   2 (-3.7A)","0.67A","5hesB-1opkA:27.3","5hesB-1opkA:20.81"],["5HES_B_032B401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"GLY A 269;VAL A 275;ALA A 288;LYS A 290;ILE A 332;THR A 334","None;P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.1A);P16 A   2 (-3.7A)","0.76A","5hesB-1opkA:27.3","5hesB-1opkA:20.81"],["5HI2_A_BAXA801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"ALA A 288;LYS A 290;GLU A 305;THR A 334;LEU A 373;HIS A 380","P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);None;None","0.55A","5hi2A-1opkA:26.4","5hesB-1opkA:20.81"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"VAL A 275;ALA A 288;LYS A 290;ILE A 332;THR A 334","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.1A);P16 A   2 (-3.7A)","0.40A","5hieA-1opkA:25.4","5hi2A-1opkA:19.80"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"VAL A 275;ALA A 288;LYS A 290;ILE A 332;THR A 334","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.1A);P16 A   2 (-3.7A)","0.40A","5hieB-1opkA:25.4","5hieA-1opkA:21.54"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"VAL A 275;ALA A 288;LYS A 290;ILE A 332;THR A 334","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.1A);P16 A   2 (-3.7A)","0.40A","5hieD-1opkA:25.5","5hieB-1opkA:21.54"],["5I9X_A_DB8A1001_1","EPHRIN TYPE-A RECEPTOR 2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"ALA A 288;LYS A 290;ILE A 332;THR A 334;GLY A 340;GLU A 348;LEU A 389","P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);None;P16 A   2 (-4.4A)","0.74A","5i9xA-1opkA:31.6","5hieD-1opkA:21.54"],["5I9Y_A_1N1A1001_1","EPHRIN TYPE-A RECEPTOR 2","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"ALA A 288;LYS A 290;MET A 309;THR A 334;GLY A 340;GLU A 348;LEU A 389","P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);None;P16 A   2 (-4.4A)","0.83A","5i9yA-1opkA:31.0","5i9xA-1opkA:25.64"],["5MO4_A_NILA601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;TYR A 272;VAL A 275;GLU A 305;ILE A 332;MET A 337;GLY A 340","P16 A   2 ( 4.2A);P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-4.1A);None;P16 A   2 (-3.4A)","0.74A","5mo4A-1opkA:54.2","5i9yA-1opkA:25.64"],["5MO4_A_NILA601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;VAL A 275;LYS A 290;GLU A 305;ILE A 332;PHE A 336;MET A 337;GLY A 340","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-4.1A);P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A)","0.58A","5mo4A-1opkA:54.2","5mo4A-1opkA:98.99"],["5MO4_A_NILA601_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"ALA A 288;VAL A 308;MET A 309;ILE A 312;LEU A 317;HIS A 380;LEU A 389","P16 A   2 (-3.4A);None;P16 A   2 (-3.3A);None;None;None;P16 A   2 (-4.4A)","0.62A","5mo4A-1opkA:54.2","5mo4A-1opkA:98.99"],["5MO4_A_NILA601_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"ALA A 288;VAL A 308;MET A 309;LEU A 317;HIS A 380;LEU A 389;ALA A 399","P16 A   2 (-3.4A);None;P16 A   2 (-3.3A);None;None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.59A","5mo4A-1opkA:54.2","5mo4A-1opkA:98.99"],["5MO4_A_NILA601_2","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"ALA A 288;VAL A 308;MET A 309;LEU A 317;VAL A 318;HIS A 380;LEU A 389","P16 A   2 (-3.4A);None;P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);None;P16 A   2 (-4.4A)","0.58A","5mo4A-1opkA:54.2","5mo4A-1opkA:98.99"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"GLY A 273;VAL A 275;ALA A 288;LYS A 290;ILE A 332;THR A 334","None;P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.1A);P16 A   2 (-3.7A)","0.83A","5p9iA-1opkA:30.0","5mo4A-1opkA:98.99"],["5TE0_A_XINA401_1","AP2-ASSOCIATED PROTEIN KINASE 1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"ALA A 288;GLU A 305;MET A 309;VAL A 318;PHE A 336;GLY A 340;LEU A 389","P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.43A","5te0A-1opkA:23.3","5p9iA-1opkA:28.11"],["5VCV_A_1N1A404_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;VAL A 318;GLY A 340","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 ( 4.7A);P16 A   2 (-3.4A)","1.07A","5vcvA-1opkA:22.9","5te0A-1opkA:19.96"],["5VCV_A_1N1A404_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;ALA A 288;LYS A 290;GLU A 305;VAL A 318;THR A 334","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A)","0.51A","5vcvA-1opkA:22.9","5vcvA-1opkA:21.26"],["5VCY_A_DB8A401_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",6,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;THR A 334","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.7A)","0.59A","5vcyA-1opkA:22.8","5vcvA-1opkA:21.26"],["5Y7Z_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.65A","5y7zA-1opkA:22.7","5vcyA-1opkA:21.26"],["5Y7Z_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.65A","5y7zA-1opkA:22.7","5y7zA-1opkA:10.27"],["5Y80_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.51A","5y80A-1opkA:22.8","5y7zA-1opkA:22.24"],["5ZV2_A_LEVA801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",8,"LEU A 267;GLY A 268;VAL A 275;ALA A 288;GLU A 305;MET A 309;GLY A 340;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 ( 4.3A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.4A);P16 A   2 (-3.5A)","0.50A","5zv2A-1opkA:31.5","5y80A-1opkA:10.27"],["5ZV2_B_LEVB801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"LEU A 267;GLY A 268;VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;GLY A 340;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 ( 4.3A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.4A);P16 A   2 (-3.5A)","0.50A","5zv2B-1opkA:31.3","5zv2A-1opkA:10.30"],["6BQG_A_ERMA1201_1","5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562","4crm","TRANSLATION INITIATION FACTOR RLI1","Saccharomyces cerevisiae",5,"SER P 249;VAL P 524;GLY P 224;ASN P 387;VAL P 254","None;None;None;ADP P1612 (-3.6A);None","1.10A","6bqgA-4crmP:undetectable","5zv2B-1opkA:10.30"],["6BSD_A_1N1A901_0","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",9,"VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;THR A 334;MET A 337;GLY A 340;LEU A 389","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 (-3.7A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.53A","6bsdA-1opkA:29.6","6bqgA-4crmP:9.60"],["6F3N_B_ADNB505_2","-","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"GLN A 319;THR A 334;HIS A 380;LEU A 403","None;P16 A   2 (-3.7A);None;None","1.28A","6f3nB-1opkA:undetectable","6bsdA-1opkA:11.21"],["6FNM_A_1N1A1001_1","-","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"VAL A 275;ALA A 288;ILE A 332;THR A 334;MET A 337;GLY A 340;LEU A 389","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.72A","6fnmA-1opkA:32.3","6f3nB-1opkA:23.78"],["6FNM_A_1N1A1001_1","-","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",7,"VAL A 275;ALA A 288;LYS A 290;GLU A 305;ILE A 332;THR A 334;MET A 337","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);None","0.81A","6fnmA-1opkA:32.3","6fnmA-1opkA:27.36"],["6GBN_A_ADNA501_2","-","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"GLN A 319;THR A 334;HIS A 380;LEU A 403","None;P16 A   2 (-3.7A);None;None","1.29A","6gbnA-1opkA:undetectable","6fnmA-1opkA:27.36"],["6GBN_D_ADND501_2","-","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"GLN A 319;THR A 334;HIS A 380;LEU A 403","None;P16 A   2 (-3.7A);None;None","1.28A","6gbnD-1opkA:undetectable","6gbnA-1opkA:21.46"],["6HD4_A_STIA604_0","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",11,"VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;ILE A 312;VAL A 318;ILE A 332;THR A 334;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.70A","6hd4A-1opkA:36.8","6gbnD-1opkA:21.46"],["6HD4_A_STIA604_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"TYR A 272;VAL A 308;MET A 337;GLY A 340","P16 A   2 (-3.6A);None;None;P16 A   2 (-3.4A)","0.76A","6hd4A-1opkA:36.8","6hd4A-1opkA:28.37"],["6HD4_A_STIA604_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"VAL A 308;PHE A 336;MET A 337;GLY A 340","None;P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A)","0.47A","6hd4A-1opkA:36.8","6hd4A-1opkA:28.37"],["6HD4_B_STIB602_0","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;VAL A 318;ILE A 332;THR A 334;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.64A","6hd4B-1opkA:36.9","6hd4A-1opkA:28.37"],["6HD4_B_STIB602_0","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;ILE A 312;VAL A 318;ILE A 332;THR A 334;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 (-3.5A)","0.70A","6hd4B-1opkA:36.9","6hd4B-1opkA:28.37"],["6HD4_B_STIB602_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;TYR A 272;VAL A 308;MET A 337;GLY A 340","P16 A   2 ( 4.2A);P16 A   2 (-3.6A);None;None;P16 A   2 (-3.4A)","0.84A","6hd4B-1opkA:36.9","6hd4B-1opkA:28.37"],["6HD4_B_STIB602_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"LEU A 267;VAL A 308;PHE A 336;MET A 337;GLY A 340","P16 A   2 ( 4.2A);None;P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A)","0.56A","6hd4B-1opkA:36.9","6hd4B-1opkA:28.37"],["6HD6_A_STIA603_0","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",11,"VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;VAL A 318;ILE A 332;THR A 334;PHE A 336;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);P16 A   2 ( 4.7A);P16 A   2 (-4.1A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.63A","6hd6A-1opkA:36.7","6hd4B-1opkA:28.37"],["6HD6_A_STIA603_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",4,"LEU A 267;ILE A 312;MET A 337;GLY A 340","P16 A   2 ( 4.2A);None;None;P16 A   2 (-3.4A)","0.86A","6hd6A-1opkA:36.7","6hd6A-1opkA:28.37"],["6HD6_B_STIB601_0","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;GLU A 305;MET A 309;ILE A 312;VAL A 318;THR A 334;PHE A 336;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-4.4A)","0.68A","6hd6B-1opkA:36.8","6hd6A-1opkA:28.37"],["6HD6_B_STIB601_0","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",10,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;MET A 309;ILE A 312;VAL A 318;THR A 334;PHE A 336","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.3A);None;P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A)","0.60A","6hd6B-1opkA:36.8","6hd6B-1opkA:28.37"],["6HD6_B_STIB601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"TYR A 272;VAL A 308;ILE A 332;MET A 337;GLY A 340","P16 A   2 (-3.6A);None;P16 A   2 (-4.1A);None;P16 A   2 (-3.4A)","0.75A","6hd6B-1opkA:36.8","6hd6B-1opkA:28.37"],["6HD6_B_STIB601_1","TYROSINE-PROTEIN KINASE ABL1","1opk","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","Mus musculus",5,"VAL A 308;ILE A 332;MET A 337;GLY A 340;ALA A 399","None;P16 A   2 (-4.1A);None;P16 A   2 (-3.4A);P16 A   2 (-3.5A)","0.58A","6hd6B-1opkA:36.8","6hd6B-1opkA:28.37"]]